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ABSTRACT 
Cardiovascular disease (CVD) and cancer are the leading causes of death worldwide. A 
damaged endothelium is one of the factors contributing towards these diseases. This thesis 
focused on understanding the implications of alterations to the physiological endothelium 
resulting in pathologies related to vascular disease and cancer metastasis.   
 Functional healing response occurs in the diseased vessel wall aimed at restoring the vessel 
after an injury. Existing studies state that vascular progenitor cells contribute to the injured 
vasculature and aid in the repair process.  Yet the mechanisms underlying the amalgamation of 
the cells to the endothelium, their origin and functions have not been clear. Through Study 1 
using animal models of arterial injury, we examined the role of bone marrow derived cells in 
arterial repair and the mechanisms behind it. We observed that bone marrow-derived cells, 
helped in the initial stages of arterial injury and were subsequently eliminated from the artery 
wall. They localized in the arterial intima and most them were of endothelial phenotype. 
Additionally, bone marrow-derived cells did not fuse with the intima but could differentiate 
into vascular cells. This helped them adjust in the vessel wall and meet the needs of their new 
microenvironment. Fascinatingly, local delivery of bone marrow-derived endothelial cells to 
the sites of arterial injury caused a 1.4-fold decrease of the intimal lesion area. These results 
define the role of BM derived endothelial cells in the development of intimal lesions post 
vascular injury and this information contributes to the existing understanding of the 
pathogenesis of intimal hyperplasia. 
Hemodynamic forces are a cause of a dysfunctional endothelium. A turbulent blood flow could 
result in vascular disease. Studies have shown that red blood cell distribution (RDW) width as 
a risk factor for death in cancer and CVD. RDW is one of the haematological parameters 
commonly reported as part of a complete blood count An RDW higher than normal is termed 
as anisocytosis. Anisocytosis has been traditionally used, in combination with the red blood 
cell corpuscular volume, to diagnose chronic inflammatory status in the body. It has been never 
studied before if anisocytosis is just factor that reflects chronic inflammation in the body, or is 
factor that directly affects it.  Hence in Study 2, we hypothesized that anisocytosis leads to 
changes in blood flow affecting interaction between blood and vascular endothelium at the 
bifurcation of arteries. We found that a high RDW is a predictive factor for the interaction 
between cellular components of blood and vascular wall. These interactions can lead to 
increased inflammation in the vessels and initiation of thrombosis. Put together, we suggest 
that anisocytosis measured by RDW is a predictive factor of vascular diseases.  
Cancer metastasis is one of the major causes of mortality and arises also due to a damaged 
endothelium. In Study 3 we investigated the role of murine cytomegalovirus(MCMV) in colon 
cancer progression using MCMV infected and non-infected animal models. Our results indicate 
that MCMV did not affect tumor growth but increases the incidence of metastasis to the lungs. 
Additionally, using microarray analysis we found cytokeratins 1, 2 and 14 to be upregulated 
100 times in the infected models compared to the non-infected. We speculate that in our case 
metastasis is mediated possibly through a cytokeratin mediated pathway. The mechanism for 
dissemination is under investigation. 
In Study 4, we investigated the effect of C/EBPβ on metastasis and the relationship between 
C/EBPβ expression and overall survival of breast cancer patients. We found that decrease in 
C/EBPβ expression was related to shorter overall survival of breast cancer patients. Loss of 
C/EBPβ also, affected tumor growth, morphology and lung metastasis in murine 4T1 breast 
cancer model. Furthermore, inhibition of C/EBPβ resulted in an augmented expression of 
MHCII and CD45+, CD3+ and CD4+ lymphocytes accumulation in the tumors. Additional 
experiments established the role of inflammation in C/EBPβ-mediated metastasis formation.   
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1 GENERAL INTRODUCTION 
Cancer and Cardiovascular diseases are the two most prominent causes of death worldwide. 
[1] Emerging evidence indicates shared risk factors and a common biology between these 
diseases. For instance, chronic inflammation has a significant role in contributing to both 
diseases. [2, 3] An alteration of the vasculature and the endothelial cells plays a key role in 
pathogenesis of CVD and cancer. [4] The widespread overlap regarding disease prevention 
and risk factors for these diseases suggest a common mechanism in terms of molecular 
pathways. [5] 
1.1 VASCULAR AGEING 
An important factor that contributes to vascular dysfunction is ageing reliant injury of normal 
endothelial functioning. This is responsible for numerous age-related illnesses of the vascular 
system and other organs. All organs undergo a progressive decline of function and structure 
over time due to ageing. Endothelial cells undergo senescence during this process and display 
substantial changes in their properties ensuing damage to the vascular functionality and neo-
angiogenic capability. Thus, changes to mechanical and structural properties of the vascular 
wall result in damage of arterial elasticity and reduced arterial compliance[1]. 
Evidence suggests that different disease state like diabetes, hypertension and end stage renal 
failure show a reduced arterial compliance. These changes could also be present before the 
manifestation of CVD. Vascular ageing contributes to the ageing dependent growth in 
atherosclerotic disease and hypertension. More than traditional risk factors like lipid levels, 
smoking, diabetes, and sedentary lifestyle, ageing is a factor that deliberates a greater risk for 
the disease. Mitochondrial dysfunction, microRNAs and micro environmental stressors like 
hypoxia, Mechanisms like mitochondrial dysfunction and micro environmental stressors, are 
defined to be involved in ageing-related endothelial cell senescence control.[2, 3] 
The process of ageing is characterized by a functional decline in the cells and tissues and the 
diminished ability to suitably respond to environmental distress, including metabolic stress and 
reduced oxygen supply. This results in deterioration of the total fitness of the organism, which 
is often associated with the individual’s life style.[4-6] As the vasculature is the major source 
of oxygen and nutrient supply in the body, endothelial cells are extremely susceptible to 
deviation in oxygen pressure. The age-related injury of the response to oxygen and nutrients 
level variation is considered a key factor contributing to arterial dysfunction that leads to age 
related vascular diseases, for example, atherosclerosis.[7, 8] 
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1.1.1 Causes  
1.1.1.1 General Mechanisms  
Many years ago, atherosclerosis was thought to be a lipid storage disease. Lipid deposits 
were formed on the artery’s surfaces and grew until they became large enough to hinder 
blood flow and eventually result in a cardiac incident such as a myocardial infarction or a 
stroke.[9] Current mechanisms involve inflammation, which play a key role in 
atherosclerosis formation, right from its initiation and progress to its endpoint-thrombotic 
complications. [10]ECs, which form the innermost layer of the arterial wall, normally resist 
the attachment of leukocytes such as macrophages and T lymphocytes from binding to its 
wall. But triggers like consuming high saturated fat diet, hypertension or smoking can 
initiate this binding. One factor is vascular endothelial growth factor-1 (VCAM-1).[11] 
Lesions also develop due to type of blood low they experience. Shear stress occurs due to 
laminar blood flow and this results in several atheroprotective mechanisms.[11, 12] For 
example, it produces an antioxidant enzyme, superoxide dismutase or an increased 
expression of nitric oxide synthase. This limit VCAM-1 expression by inhibiting nuclear 
factor kappa beta(nF-Kbeta) production and thus combat platelet clumping.[13] 
Once adhered, the monocytes penetrate the endothelium and infiltrate the intima by 
diapedesis a process that requires a chemoattractant gradient such as monocyte 
chemoattractant protein -1(MCP-1).[14] Within the intima, monocytes change into 
macrophages, and express scavenger receptors and inundate lipid particles, thus 
transforming into foam cells typical of atherosclerotic lesions.[15, 16] In the intima through 
lesion evolution the T lymphocytes join macrophages and secrete cytokines and growth 
factors that may nurture the migration and proliferation of smooth muscle cells. T 
lymphocytes also excite macrophages to produce collagen-degrading enzymes and secrete 
cytokines and growth factors that may promote the migration and proliferation of smooth 
muscle cells. This results in the fibrous cap protecting the blood from the thrombogenic core 
of the plaque, to weaken leading to rupturing of the plaque and eventually resulting in 
thrombosis which is the complication in most atherosclerotic cases.[17, 18] 
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1.1.1.2 Dysfunctional Endothelium 
A normal vasculature has an organized network of blood vessels maintained by a balance 
between pro and anti-angiogenic factors.  
A healthy tissue also displays a systematic network of lymphatic vessels that allows for 
transport and draining of blood and metabolic waste from the interstitium. This intricate 
architecture consisting of mature vessels make up the normal vasculature. These vessels allow 
the adequate transport of nutrients, oxygen and blood supply required to sustain the 
vasculature.[19, 20] Alterations to the vasculature plays a significant role in the development 
of numerous diseases.[21] 
The endothelium plays a significant role in governing the circulation as a physical barrier and 
as a variety of different regulatory substances. For example, the endothelium derived 
prostacyclin and nitric oxide inhibit platelet function and induce vascular relaxation when they 
are released in response to physical stimuli, platelet derived substances or hormones. The 
endothelium is also a good source of heparins, heparin sulphates, thrombospondins and platelet 
derived growth factor. Also, several vasoactive substances produced by the endothelium such 
as nitric oxide, angiotensin- 2 and endothelin-1 might play a role in vascular tension. 
Dysfunction of these endothelium dependent factors could lead to CVD such as atherosclerosis 
and hypertension and is thought to be involved in stroke, tumor angiogenesis, vascular leakage 
and infectious diseases[22] 
Endothelial dysfunction occurs when the endothelium shifts to a pro inflammatory, reduced 
vasodilatory and pro thrombotic state. This state is associated with most forms of 
cardiovascular diseases. When free radicals disrupt the balance of NO in the body, damage to 
the endothelium occurs leaving them excessively permeable allowing for toxins to pass into 
the tissues.[23] When the action of NO is inhibited, endothelial signaling is weakened resulting 
in numerous diseases, since in the human body, the endothelium actively maintains, around 
60,000 miles of blood vessels. A normally functioning endothelium also supports the body's 
immune response, helps regulate blood clotting, controls the volume of fluid and the number 
of electrolytes and other substances passing from blood into the tissues, and produces dilation 
or constriction of the blood vessels.[24] 
1.1.1.3 Hemodynamics 
The dynamics of blood flow is called hemodynamics.[25] Blood, being a non-Newtonian fluid, 
is best studied with rheology.[26] 
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Normal blood flow ensures the transportation of nutrients, oxygen, CO2, metabolic waste 
throughout the body thus enabling regulation of different functions such as maintaining cell 
metabolism, pH and osmotic pressure and temperature regulation along with protecting the 
body from harmful stimuli.  
These are key factors that helps the body adapt as per the environment.[25] A laminar blood 
flow thus ensures proper functioning of the body while a turbulent flow and local 
hemodynamic factors like flow disturbances at bends and bifurcations contribute to the 
formation of atherosclerosis or other pathological conditions. A laminar flow occurs when 
the vessel wall is smooth whilst a turbulent flow occurs when there is a decrease in wall 
smoothness. This is due to fatty deposits on the vessel wall.[27] 
The vascular ECs form the innermost layer of the vessel wall with direct contact to blood 
flow and are involved with vital homeostatic functions to various mechanical and chemical 
stimuli.[28] [29-33] Not only do they provide a selective barrier for permeability but the 
EC’s also influence hemostasis and thrombosis through secretion of pro and anti-coagulants, 
fibrinolytic agents and mediate inflammatory responses via the release of cytokines and 
chemokines. The EC’s also regulate smooth muscle migration through the release of 
vasodilators and constrictors and influence vascular remodeling using growth promoters and 
inhibitors. [34]Hence hemodynamic forces are needed for normal physiological functioning 
of the EC’s while some forces induce a dysfunction of the endothelium by modulating EC 
gene expression and signaling leading to the development of pathological states, which 
contribute to the formation of atherosclerosis, thrombosis and its complications.[35-38] 
The role of hemodynamic forces in endothelial dysfunction was first proposed when 
observations of initial atherosclerotic lesions were credited to a nonrandom pattern of 
development. These were observed typically at arterial bends and branches with a disrupted 
flow. This flow pattern included recirculation eddies and change in direction with respect to 
space (reattachment and flow separation) and time (reciprocating flow).[39-42] 
Recent research show that this kind of flow and the associated reciprocating and low shear 
stress bring about a constant activation of several atherogenic genes in ECs. for instance, 
the monocyte chemoattractant protein (MCP-1) that induces monocyte infiltration into 
arterial wall, and platelet derived growth factor (PDGF) that augment EC turnover and SMC 
migration, into the subintimal space.[28, 34, 43-45] 
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On the contrary, the straight portion of the artery, usually safe from the atherosclerotic lesions, 
is exposed to constant laminar blood flow and high shear stress, all with a definite direction of 
flow and the associated downregulation of atherogenic genes and upregulation of growth arrest 
genes and anti-oxidants in EC’s.[28, 43, 46-48] Hence these findings propose that laminar and 
turbulent flow patterns might induce a variety of molecular responses in ECs, which result in 
sparing of the straight parts of the arteries and formation of lesions at the curvatures.[49, 50] 
1.2 BLOOD AND BLOOD VESSELS 
1.2.1 Blood 
Normal tissue functioning requires an adequate supply of oxygen, nutrients and blood vessels 
to facilitate their transport. Virchow, around a hundred and fifty years ago, explained vascular 
diseases in terms of cellular mechanisms, most of which stand valid till date.[51, 52] However, 
more recently the vessel wall has been visualized as a channel containing blood, which is 
provided by the heart pumping around blood in a circuit that is optimized to exchange and 
distribute oxygen and nutrients. 
Blood is a body fluid that delivers oxygen and the essential nutrients to cells and tissues.[53] 
In vertebrates, blood is comprised of blood cells suspended in blood plasma. Blood has various 
functions such as, supplying oxygen to different tissues, supply of nutrients like amino acids, 
fatty acids and glucose, waste removal (CO2, urea) etc. Blood cells constitute the following 
components; erythrocytes, leukocytes, platelets. The most abundant are the erythrocytes, which 
has the iron containing protein, the hemoglobin, which facilitates transport of oxygen [54-56]. 
The cellular components of blood are formed through a process known as hematopoiesis, which 
is a process that occurs during embryonic development and throughout adulthood.  All the cells 
are derived from the hematopoietic stem cells [57]. In a healthy adult, around 10^11-10^12 
new cells are formed every day [58]. The process occurs in two waves. The primitive wave 
consists of an erythroid progenitor, which appears in blood islands, giving rise to macrophages 
and erythrocytes during initial stages of embryonic development [59] [60]. The main purpose 
of this stage is to provide tissue oxygenation since the embryo grows rapidly. This wave is 
transitionary. In humans, fetal haematopoiesis begins in the yolk sac and shifts to the liver 
briefly before establishing in the bone marrow and thymus when the baby is born.[61, 62] The 
definitive wave follows and includes haematopoietic stem cells. They are multipotent which 
can produce all blood lineages of the adult organism.[63]. 
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Bone marrow is the tissue encompassing the center and the epiphysis of bones.[64]It is also the 
place for production and maturation of B cells. It is an organ composed of trabecular and 
cortical   bone, cartilage, hemopoetic and connective tissues. The trabecular bone is composed 
of a framework of fine bone plates filled with hematopoietic marrow, fat containing marrow or 
blood vessels.[65] The bone marrow consists a vascular component (stroma) and a 
hematopoietic component (parenchyma) The parenchyma includes hematopoietic stem cells 
(HSCs) and hematopoietic progenitor cells, localized near the endosteum of the bone and more 
around blood vessels.  
The stroma comprises multipotential non-hematopoietic progenitor cells as well which can 
differentiate into various tissues of mesenchymal origin, including, endothelial cells, 
osteoblasts, reticular cells, adipocytes and fibroblasts. The stromal cells including ECs deliver 
signals for migration of specific leukocytes into and out of the bone marrow, including in 
rolling/extravasations along the vascular endothelium.[65, 66] 
1.2.2 Blood vessels 
 
 
 
 
 
 
 
 
 
Fig 1. Structure of the vessel wall 
Angiogenesis is a process through which fresh blood vessels are formed from existing 
vessels. It is a normal and key process that occurs throughout life and is involved in 
development and growth, disease as well as wound healing. Oxygen plays a critical role in 
this process along with hemodynamic factors that are essential for the survival of vascular 
networks and for structural adaptations of vessel walls. [67-70] 
External 
elastic 
lamina 
Tunica intima 
(endothelium) 
Elastic membrane 
Tunica media 
Tunica externa 
(adventitia) 
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The blood vessels originate through a process beginning with the mesodermal layer. The first 
system to develop in the embryo is the cardiovascular system. [71]The luminal surface of this 
system that is in close contact to the blood is made up of a single layer of endothelial cells 
derived from the mesoderm. It is formed by the following processes. Hematopoietic stem cells 
and angioblasts arise from the differentiation of hemangioblasts followed by vasculogenesis 
which is the de novo formation of blood cells from angioblasts.  
It is an active process that involves cell to cell interactions along with cell to extracellular matrix 
interactions. This process is directed spatially and temporally by morphogens and growth 
factors. Vasculogenesis includes differentiation of mesoderm stem cells into angioblasts 
followed by migration of angioblasts to form blood islands where they give rise to endothelial 
cells.[72, 73] 
There are two types, the sprouting and intussusceptive angiogenesis. Sprouting angiogenesis 
occurs when sprouts of endothelial cells migrate towards a stimulus, in this case VEGF-A. It 
thus adds vessels to parts of tissues that previously lacked blood supply. Intussusceptive, on 
the other hand forms blood vessels by splitting vessels due to which interstitial fluids invade 
an existing blood vessel. [74, 75] 
The steps involved in sprouting angiogenesis process are: Basement membrane degradation 
followed by endothelial cell (EC) proliferation, focused migration of the cells, formation of 
new vessels (tubulogenesis), fusion of the vessels, vessel pruning and pericyte stabilization. 
The process begins in response to a hypoxic environment. VEGF-A initiates the process.[76-
78] An endothelial tip cell responds to this stimulant by guiding the sprouting EC through the 
ECM towards VEGF-A.[79] The ECs migrate through the ECM via filopodia, which are long, 
thin projections which extend from the migrating tip of the cells. 
These secrete proteolytic enzymes which degrade the basement membrane. When enough 
filopodia have anchored to the substratum, the tip cell is aligned with the VEGF-A receptor 
through contractions of actin filaments within the tip cell. Meanwhile, the capillary sprout 
elongates due to endothelial stalk cell proliferation, since they follow the tip cell causing the 
elongation process. A lumen is formed within a series of stalk cells due to vacuoles developing 
and coalescing. These stalk cells form the trunk of the recently formed capillary. When the tip 
cells of two or more capillary sprouts encounter at the origin of the VEGF-A secretion, the tip 
cells merge together forming a continuous lumen via which oxygenated blood can flow. VEGF-
A levels return to near normal, when the local tissues obtain suitable amounts of oxygen. 
Pericyte recruitment induces maturation and stabilization of the capillary.[80-82] 
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Intussusceptive angiogenesis also called splitting angiogenesis, is a process where a single 
vessel splits in two due to an extension of the vessel wall into the lumen. This type is quick and 
effective compared to sprouting angiogenesis since, initially, it only requires restructuring of 
existing ECs and does not require immediate EC proliferation or migration. Intussusceptive 
angiogenesis occurs lifelong but plays an important role in vascular development in embryos 
where development is quick and resources are limited. Intussusception mainly causes new 
capillaries to develop from existing capillaries.[83-85] 
All blood vessels except for capillaries are made up of three layers, tunica intima, tunica media 
and the adventitia. The tunica intima, the thinnest layer is comprised of a monolayer of 
endothelium cells that line the vessel wall, surrounded by an elastic connective tissue called 
the internal elastic lamina.[86] [87], whose function is to related to elastic resilience to sustain 
blood pressure  The tunica media is made up of numerous layers of elastic lamina and smooth 
muscle cells. This is the thickest layer. The SMC’s present in the medial layer influence blood 
pressure through the production of multiple ECM components (elastin, collagen).[88] The 
adventitia is comprised of loose connective tissues made up, primarily of collagens and elastic 
fibers, fibroblasts and macrophages. The fibroblasts play an important role in fibrognesis. The 
adventitia also plays a significant role in vascular remodeling and development of vascular 
diseases such as transplant vasculopathy, atherosclerosis, hypertension and restenosis. [89, 90] 
1.3 VASCULAR REMODELING  
Vascular remodeling is an intricate process of structural changes that involve at least four 
different process – cell growth and death, cell migration and degradation of extra cellular matrix 
(ECM). The process is dependent on an interplay between locally generated growth factors, 
hemodynamic stimuli and vasoactive substances. 
Generally remodeling is an adaptive process which occurs in response to long term changes in 
the hemodynamic conditions, but it might eventually contribute to pathophysiology of 
circulatory disorders and vascular diseases. [91, 92] For instance, physiologically, vascular 
remodeling occurs during pregnancy. Adequate uteroplacental blood flow is needed for a 
normal pregnancy outcome. This process takes place with the growth and remodeling of the 
uterine circulatory system along with growth of a new organ, the placenta. 
Vascular remodeling involves various patterns and the nomenclature used to denote these 
patterns is circumferential remodeling. It is normally called inward or outward to signify 
tapering vs widening of the vessel wall. The term expansive remodeling is used to denote 
increase in circumference and it is employed as a substitute for outward These terms were 
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primarily proposed by Mulvany.[93] Also, taken into consideration is the wall mass, which can 
increase (hypertrophy), decrease (hypotrophy) or remains unchanged (eutrophy). For example, 
the remodeling of vessel to larger lumen with the same wall thickness occurs during pregnancy 
in the uterine circulation. This is called outward hypertrophic because the cross-sectional area 
is increased. This is due to the diameter of the chief uterine artery almost doubling in magnitude 
in humans during pregnancy and the enlargement occurs with or without the thickening of the 
vascular wall. Another study on human myometrial radial arteries from preeclamptic women 
the pattern of remodeling was inward eutrophic since there was no change in cross-sectional 
area indicating a rearrangement of existing wall elements around a smaller lumen.[94, 95] 
Several factors contribute to vascular remodeling resulting in pathological implications. For 
example, when pulsatile blood flow and pressure induce various kinds of hemodynamic forces 
such as shear stress, hydrostatic pressure, constantly on blood vessels. Since the ECs are 
exposed to flowing blood, they bear most of the shear stress because of frictional forces rising 
from blood flow corresponding to the vessel luminal surface. [30, 34, 96]This increase or 
decrease in shear stress plays a key role in vascular remodeling and homeostasis.  [97-100] 
During the process of remodeling, for a compensatory arterial response towards changes to 
occur, a functional and intact endothelium is required to undergo adjustments in function and 
structure in response to alterations in shear stress.[98] 
Vasoactive factors also play an important role in vascular structure determination. They have 
an    acute effect on vascular muscle tone and they may also impact matrix production and 
migration of cells. Angiotensin 2, for example, induces growth of vascular smooth muscles 
cells through PDGF AA and TGF beta 1.[101-103] They are also involved in activation of EC 
through receptors coupled to ion channels which in turn modulate intracellular calcium 
concentration.[104] 
Vascular remodeling can also occur in response to increased arterial pressure, in which case, 
the structure of the vessel wall is modified such that the ratio of the width of the wall to the 
width of the lumen is raised either, by an increase in muscle mass or rearrangement of cellular 
and non-cellular elements. This results in heightened peripheral resistance typical for 
hypertension. [105-107] 
Another form of remodeling includes reduction in lumen diameter and is related to other 
diseases such as cardiac allograft vasculopathy and restenosis post percutaneous 
intervention.[108] Alternatively, remodeling could also lead to higher lumen diameter and 
compensate for increased plaque load. [109]Vascular remodeling also involves changes 
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primarily in lumen dimensions due to active reorganization of wall components. This type is 
associated with constant high blood flow, observed in patients -an arteriovenous fistula and 
was shown in animal models.[110, 111] 
Remodeling of vessel wall also occurs in response to vascular injury. A neointima forms in a 
sequential process as part of a reparative answer to injury. This involves thrombosis, migration 
and proliferation of vascular cells, matrix production, and inflammatory-cell infiltration. 
Mechanical injury results in vessel constriction and smaller vascular lumen in response to the 
scarring in the outer vessel layer. Key features of transplant vasculopathy include inflammation 
and formation of intimal hyperplasia.[108, 112, 113] 
1.3.1 Vascular injury  
Vascular trauma is the injury caused to a blood vessel- the artery, that carries blood to an organ, 
vein, which returns blood back to the heart.[114] Hemodynamics, hypoxia, ischemia and 
endothelial dysfunction are factors that contribute to vascular injury. Vascular injury is brought 
about by mechanical injury due to surgical manipulations and from tissue ischemia due to 
obstruction of the vasa vasorum. The level of the resulting neointimal lesion is related to the 
extent of vascular injury.[115, 116] 
Distressed flow patterns contribute to pathogenesis of various clinical disorders such as 
atherosclerosis, arterial aneurysm, post-surgical intimal hyperplasia, ischemic/reperfusion 
injury. This is due to disturbances of blood flow in arteries generated due to surgical 
interventions like end to end anastomosis in bypass graft or stent insertion in balloon 
angioplasty. [117]Additional flow disturbances that facilitate endothelial dysfunction is the 
termination or inactive flow and its recovery later in clinical conditions related with 
ischemia/reperfusion and hypoxia injury. Hence myocardial recovery following acute 
infarction becomes complex and the outcome could be cell damage, arrhythmia and death.[118] 
Tissue injuries induced by solid organ transplantation, tissue resuscitation and key vascular 
surgical intrusions could also result in a dysfunctional endothelium. This results in 
inflammatory responses with recruitment of WBCs from circulation.[119-121] 
Another mode of injury occurs through ischemia/hypoxia. Hypoxia is a vital component of an 
ischemic result. Hypoxia is the reduction of oxygen while ischemia is the lack of perfusion. 
Ischemia is a process, which occurs when the tissue’s demand for energy substrates is not met 
with supply.[122, 123] Reperfusion injury or ischemic/reperfusion injury occurs when blood 
flow and oxygen resume to a tissue after a hypoxic/ischemic event. HIF 1 alpha is stabilized in 
response to limited oxygen. This is worsened by modification of locally released vasoactive 
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mediator such as NO and its action. Sudden re-oxygenation post hypoxia activates the release 
of free radicals, like reactive oxygen species (ROS) and reactive nitrogen species (RNS), which 
modify EC homeostasis and results in swelling and tapering of the blood vessel lumen along 
with a host of other damaging effects. ROS and RNS are highly reactive molecules and include 
hydrogen peroxide, peroxynitrite, hydroxyl radical, and superoxide resulting in oxidative 
stress, disparity between the production of reactive species and antioxidant defences that causes 
tissue damage. Tissue injury is characterized by a loss of tight junctions, leading to augmented 
permeability, separation from the basement membrane, and, often, EC apoptosis or necrosis. 
Eventually these structural changes contribute towards microvascular perfusion 
impairment.[124, 125] 
1.3.2 Intimal hyperplasia  
Intimal hyperplasia is the universal response of a vessel to an injury. It is the thickening of the 
tunica intima.[126] It is connected to increased cell number and the amount of ECM in the 
intimal layer of the vessel.[127] Physiologically, it occurs in the involution of the uterus, during 
closure of the ductal arteriosus post birth (DA) In the foetus, the process of intimal thickening 
starts in the second trimester of pregnancy with the build-up of glycosaminoglycans in the sub 
endothelial region (SER). This is followed by separation of ECs from the internal elastic 
lamina, followed by migration of SMCs into the sub endothelial region. This phenomenon was 
also observed in the mature DA in the neonate, indicating that this is a constant process. [127] 
[128] 
Pathologically, it occurs post balloon angioplasty[129], transplantation[130], artery bypass 
conduits[131], in pulmonary hypertension[132] and pre-atherosclerotic lesions.[133] 
Intimal hyperplasia occurs in a few stages. The key stimuli are inflammation, injury and 
enhanced vessel wall stress. [134]For instance, balloon injury to the rat carotid artery does not 
incite a marked inflammatory response but nonetheless generates intimal hyperplasia. 
Inflammation is, nevertheless, a confounding feature of most other models of vascular 
injury and therefore may contribute to the extent of intimal hyperplasia. [135]Direct effects of 
inflammatory mediators on early transduction events, mainly the NF-κB pathway, have been 
implicated. Synergistic communication between growth factors and inflammatory cytokines to 
cause MMP induction and activation is another probable mechanism. In addition, proteases 
and growth factors directly derived from macrophages possibly play key roles.[135-138] 
Two situations which evidently demonstrate a relationship between increased mean wall stress 
and intimal hyperplasia are vein grafting and pulmonary hypertension.[134] The mediators 
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involved remain largely undefined but increased MMP and PDGF expression has been 
observed in experimental (pig) vein grafts and was reversed in parallel with intimal hyperplasia 
when the grafts were supported by an external stent.[139-141] 
The injured artery recruits inflammatory cells such as macrophages and leukocytes and 
mobilizes vascular progenitor cells from their niches. Another crucial factor in the neointima 
formation, platelet-derived growth factor (PDGF), FGF along with additional factors, is 
produced by platelets, smooth muscle cells, endothelial cells and macrophage foam cells. [86] 
These factors along with PDGF act as chemo attractants, which promote cell migration of the 
SMC’s into the neointima from the media. Also, PDGF promotes production of collagens and 
proteoglycans. In parallel, the   ECM is remodelled by MMP’s, which    further promote SMC 
migration. Thus, the neointima grows in response to cell proliferation, increased ECM 
synthesis, apoptosis and fibrosis.[86, 142] 
Various sources of cells contribute to neointima formation. They can originate from the 
adventitia from cells such as pericytes, fibroblasts and vascular progenitor cells or from 
circulating progenitor cells, for example- endothelial progenitor cells, smooth muscle 
progenitor cells or bone marrow derived cells.[143, 144] 
In this thesis, through study 1, we investigated the role of intimal hyperplasia in vascular 
remodeling post balloon injury and carotid ligation in a mouse model.  
1.4 CANCER  
Cancer is a disease involving abnormal cell growth, which arises when cells undergo 
uncontrolled proliferation and lose their ability to control apoptosis. More than two hundred 
diverse types of cancer exist, and their etiology remains uncertain. Current hypothesis state that 
cancer is a genetic disease and numerous mutations in various genes are considered as cancer 
promoting genes. Additional factors such as lifestyle, obesity, tobacco, alcohol consumption 
and virus infections constitute risk factors for cancer development [145, 146] 
Dysfunctional endothelium is a hallmark of many diseases like diabetes mellitus, 
atherosclerosis and cancer.[147] Endothelial cell migration is a vital component of 
angiogenesis and requires a tight regulation of the contractile and noncontractile conditions of 
the cell. These processes require the combination of signals elicited by hepatotactic, 
chemotactic and mechanotactic stimuli. This movement is in turn, related to the activation of 
intracellular pathways that congregate on cytoskeleton remodelling.[148, 149] 
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There are several types of malignancies that affect humans and they are classified based on the 
type of cell that the tumor cells resemble. These include carcinomas representing a group of 
cancers originating from epithelial cells, including the most common cancers breast, colon, 
lung and prostate cancer, - Sarcomas a neoplasm derived from connective tissue (e.g. bone, 
cartilage, fat), originating from mesenchymal cells outside the bone marrow and lymphomas 
and leukaemia’s: neoplasm arising from blood cells that leave the bone marrow and mature in 
lymph nodes and blood.[150] 
1.4.1 Normal and Tumor Vasculature 
There are fundamental differences between the normal and tumor vasculature. The normal 
vasculature has an organized network of blood vessels maintained by a balance between pro 
and anti-angiogenic factors. A healthy tissue displays a systematic network of lymphatic 
vessels that allows for transport and draining of blood and metabolic waste from the 
interstitium. This intricate architecture consisting of mature vessels make up the normal 
vasculature. These vessels allow the adequate transport of nutrients, oxygen and blood supply 
required to sustain the vasculature. [20, 151] 
The tumor microenvironment consists of different cell types such as endothelial cells, pericytes, 
and fibroblasts. These cells contribute through the rearrangement of the ECM and secretion of 
various growth factors and cytokines to tumor progression. 
In tumors, aggressive neoplastic growth is accompanied by an over expression of pro 
angiogenic factors which lead to the formation of aberrant blood vessels. These blood vessels 
are immature and highly permeable and give rise to a disorganized vascular structure comprised 
of irregular vessels with different shapes and diameters. This is due to the scarcity in smooth 
muscle cells and possible discontinuous endothelial cell lining with an abnormal basement 
membrane. [152, 153] Augmented vessel permeability leads to deviation in osmotic forces that 
results in buildup of vascular contents and high interstitial fluid. Blood flow is hindered due to 
resistance caused by the defective shape of the blood vessels.  This, in turn, leads to insufficient 
oxygen supply with a localized hypoxia.[154, 155] 
Other aberrant characteristics of the tumor vasculature include arteolar-venous shunts 
abnormal bulges and plasma channels lacking red blood cells. The typical blood vessel 
arrangement found in the healthy tissue (consisting of arterioles, arteries and venules) 
sometimes cannot be identified. The vessel endothelial cells are dysfunctional and loose their 
expression of endothelial markers. The lymphatic vessels in tumors are also leaky, unstable 
and dilated. Due to this type of arrangement, various functional processes within the tumors 
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are drastically different to those of the healthy tissue. For instance, the normal processes of 
nutrient delivery through these dysfunctional blood vessels and of metabolic waste removal via 
the lymphatic system are greatly reduced. [20, 153] 
1.4.2 Angiogenesis in cancer 
Angiogenesis is a process through which new blood vessels form from existing vessels. It is a 
normal and key process involved in development and growth, as well as in wound healing. It 
is however, also involved in cancer, since it is the fundamental step for a tumor to grow in size 
and metastasize. Tumor angiogenesis was first reported in 1971 by Judah Folkman. He 
suggested that tumor growth is dependent on angiogenesis.[67-70] 
For a tumor to grow (more than 1-2 mm in diameter), it needs an independent blood supply, 
hence angiogenesis is a necessary step. The tumor secrets growth factors that recruit new blood 
vessels. The process continues after a tumor matures and is a vital step in sustained tumor 
growth and for tumor metastasis.[156-158] 
The newly formed vessels provide an exit route for tumors cells, through which cells may 
detach from the primary tumor and enter the blood stream. The angiogenesis process is 
regulated by the production of various angiogenic stimulators. This includes members of the 
VEGF and FGF families along with regulating angiogenic inhibiting factors like angiostatin 
and endostatin. The latter regulate and modulate the process both at the primary and metastatic 
sites. Vascular density plays an important role as a prognostic factor for many tumors. Highly 
vascular tumors are more metastatic.[159, 160] 
Regulation of angiogenesis occurs through hypoxia or ischemia. Many proangiogenic factors 
and their receptors maybe modulated by this process. For example, factors like VEGF, FGF, 
and TGF-beta, PIGF and angiopoietins and HIF. Oxygen deficiency stimulates and regulates 
HIF which in turn triggers genes for VEGF- A and VEGFR 1. The VEGF family is the most 
important player in angiogenesis. [161-167] 
VEGF induces vascular endothelial cell proliferation and growth and survival. The VEGF 
family consists of various receptors, namely VEGF- A, VEGF-B, VEGF-C and VEGF-D with 
their receptors VEGF -1, VEGF-2 and VEGF-3. VEGF-A along with the receptor VEGF -2 
are important regulators of angiogenesis. 
VEGF initiates angiogenesis by binding to specific receptors. When a tumor needs to grow, it 
releases growth factors, VEGF which binds to the extracellular receptor on the endothelial cell 
on the blood vessel.  VEGF A, B and PIGF bind to VEGF 1, while VEGF A, C and D to VEGF 
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-2. VEGF C and D bind to   VEGF 3 on the endothelial cell of the lymph vessel thereby 
stimulating lymph angiogenesis. [157, 168] 
Once VEGF binds, dimerization of the receptors takes place which activates intracellular 
tyrosine kinase domain (ITK) thereby inducing auto phosphorylation. This further activates 
downstream signals required for the angiogenesis process. 
 
 
 
 
 
 
 
 
Fig 2. Angiogenesis process 
1.4.3 Colon cancer 
Colon cancer is one of the foremost causes of cancer-related deaths worldwide. The chief cause 
of mortality in colon cancer patients is liver metastasis, either present already at cancer 
diagnosis stage, or developing after primary tumor resection. Survival rates of patients continue 
to increase with time, mainly because of improved diagnostics and treatment. [169]Colonic 
epithelium consists of roughly ten million invaginations, called crypts whose base of contain 
multiplying daughter cells and dividing stem cells and form the starting point for the cell 
migration towards the epithelium surface. Here the cells die and become replaced by 
continuously streaming new cells.[170] 
One of the factors or an amalgamation of chromosomal instability(CIN), CpG island 
methylator (CIMP) phenotype, microsatellite instability(MSI) contributes to colon cancer 
progression. Genetic variability is usually caused by loss of heterozygosity and aneuploidy. 
Alternatively, mutations in the cell cycle genes or tumor suppressor gene may also lead to 
cellular transformation. Similarly, microsatellite instability and mutator phenotype are caused 
due to epigenetic and/or genetic modifications resulting in impaired cellular pathways, such as 
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DNA repair mechanism. Non-coding RNAs, more prominently microRNAs and long non-
coding RNAs have also been implicated at numerous CRC stages.[171] 
The acquisition of mutations in the adenomatous polyposis coli (APC), followed by the 
mutational activation of oncogene KRAS and the inactivation of the tumor suppressor 
gene, TP53 signals the beginning of the CIN pathway. [172] The major players in CIN tumors 
are loss of heterozygosity (LOH) and aneuploidy. This not only constitutes most of the sporadic 
tumors (85%) but also involves familial adenomatous polyposis cases linked with germline 
mutations in the APC gene.[173] Promoter hypermethylation of several tumor suppressor 
genes is a characteristic feature of CIMP pathway most importantly MGMT and MLH1. This 
is often associated with BRAF mutation and microsatellite instability. [174]Inactivation of 
genetic alterations in short repeated sequences contributes to the MSI pathway. Also, 
hypermethylation of DNA mismatch repair gene might lead to MSI.[175] 
Both genetic and environmental factors contribute to histopathological changes. Key 
environmental factors involve toxins, pathogen invasion, polyamines, ROS (reactive oxygen 
species) production and stress. [176] 
The growth of adenomas is triggered by adverse conditions   like bacterial or viral invasions, 
subsequently causing mutation in the APC (Adenomatous Polyposis Coli) regulatory pathway 
usually affecting either APC or β-catenin. APC represses β-catenin, which diminishes the 
tendency to abnormal tissue expansion by augmenting protein expressions that promote and 
affect cell division and cell adhesion. As cells migrate from base crypts towards the epithelium 
surface, APC expression increases and hinders β-catenin. This in turn promotes apoptosis at 
the surface and provides optimal balance in production from the crypt base in parallel.[177] 
Transformation of dysplastic epithelium (stage I) to early adenoma phase (stage II) takes place 
due to COX2 mutations and appear in most human colorectal adenocarcinomas. This is 
followed by mutations in RAS genes, with K-RAS being the most common gene and less H-
RAS the least. K-RAS mutations, next to common mutations in DCC, MLH1 and MSH2 
facilitate the transition from early to late adenoma (stage III). Lastly, progression to tumor 
metastasis (stage IV), involves genes such as BAX, E2F4, MSH3, MSH6, TGF-βR2, BAX and 
MMPs, p53 and SMAD4 affecting liver, lungs, bone and brain.[178] 
1.4.4 Metastasis  
Metastasis is a multi-step process involving a modulation of phenotype of cancer cells, 
invasion of cells to enter circulation and form distal metastasis. It is one amongst the 
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hallmarks of cancer with circulating tumor cells being the prime cause in the formation of 
distal metastasis. Metastasis is the key factor for cancer related deaths. Thus, understanding 
the mechanism of tumor dissemination is the central factor of cancer research. In cancer 
patients, the disseminated tumor cells are detectable in the peripheral blood as circulating 
tumor cells (CTC’s) while in the lymph nodes they are detected as disseminated blood cells 
(DTC’s). Hence the identification and characterization of these cells have resulted in 
perceptions of the molecular mechanisms of metastasis.[179] 
Metastatic disease accounts for majority of cancer related deaths. Metastases are believed to 
develop from dormant circulating tumor cells that are seeded into various organs. The process 
of metastasis formation involves an invasion-metastasis cascade of events. A stepwise 
progression is proposed. First, the normal cells undergo genetic alterations leading to the 
formation of pre-malignant lesions.[180] These steps are clinically recognized. Several types 
of pre-malignant lesions such as hyperplasia or dysplasia, can be detected in different organs 
prior to the formation of a malignant tumor. The lesions are caused either by genetic alterations 
or by an external factor (for example, a virus infection); the former causes a monoclonal 
expansion of cells, whereas the latter causes a polyclonal expansion of cells. Unknown factors 
precipitate pre-malignant lesions to develop into cancer. Further progression leads to invasive 
cancer, with a substantial risk of metastases. [197-198] 
A metastatic tumor is composed of cells that are phenotypically different and heterogeneous, 
when compared to a noninvasive tumor.  
They are believed to origin form circulating tumor cells that have left the primary tumor and 
can reach distal organs through the lymphatic system or via the blood circulation. Once there, 
they extravasate and invade the parenchyma and form micro -metastasis that can later develop 
into macroscopic metastasis. Loss of endothelial cell integrity and a selective permeability of 
the endothelium provides for the transmigration process.[181-184]  Several factors including 
an inflammatory environment are believed to aid in the survival of tumor cells in other organs. 
Angiogenesis also provides an exit route for metastatic cells. This is due to the nature of 
permeable and immature vessels formed within the tumor leading to cells detaching and 
entering circulation. Thus, a highly vascularized tumor gives rise to more metastasis compared 
to less vascularized tumors. Butler et al showed that about 2x10^6 mammary carcinoma cells 
are shed from the primary tumor each day, some of these cells may be capable of giving rise to 
metastasis. [185] 
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The most important correlation between angiogenesis and metastasis are the studies on vascular 
density of the tumor and patient survival. A study by Weinder et. al. proposed a direct link 
between tumor vascularization and metastasis in breast cancer and suggested that this 
information can function as an independent prognostic factor for patient outcome. This study 
was repeated by others and the findings were confirmed and are not limited to breast cancer. 
Thus, these studies show the importance of vascular density in tumor aggressiveness[184, 186] 
The blood system is considered as the main mode for metastatic spread, but increasing evidence 
shows that the lymphatic system could play an important role in metastasis as well. [187] 
The lymphatic capillary is a thin walled structure comprising a single layer of endothelial cells 
lacking inter -endothelial tight junctions. They do not have smooth muscle cells and a basement 
membrane as the blood capillaries. The key function of the lymphatic vasculature is to regulate 
of tissue fluid homeostasis, antigen collection from peripheral tissues, and to mediate immune 
cells such as antigen-presenting dendritic cells to move from the periphery to lymph nodes. It 
also provides a one-way transport system that relies on skeletal muscle contraction for the 
transport of lymph.  
Lymphangiogenesis is the process of formation of new lymphatic vessels from preexisting 
vessels. It plays a significant role in tissue homeostasis. An impaired vessel or excessive 
formation of the vessel may promote the metastatic process. Generally, lymphatic vessels were 
thought to be indirect participants in tumor metastasis by providing conduits for tumor cells to 
transfer into draining lymph nodes, but recently the discovery of numerous key lymphatic-
specific molecular markers and an augmented accessibility of in vitroand in vivo experimental 
systems to study lymphatic biology have pointed towards a more dynamic role for the  
This is a process which occurs in adults only during pathological conditions such as 
inflammation, tissue repair or tumor growth. Many molecular factors that contribute to 
lymphangiogenesis have been studied recently, among which VEGF C and D bind to the 
VEGF-3 receptor expressed on the endothelial cells of the lymphatic vessels and promote this 
process. [188-190] 
More recently, numerous factors with pro lymphangiogenic activity have been recognized. 
These comprise of hepatocyte growth factor (HGF), which binds to the c-met 
receptor, angiopoietin-1 together with its endothelial cell–specific receptor Tie-2, FGF1 and -
2, PDGF, insulin-like growth factor-1 and -2, and endothelin-1. [191-195] 
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Tumor-induced lymphangiogenesis is mediated by lymphangiogenic growth factor produced 
and secreted by the tumors. The role of VEGF-C and VEGF-D in cancer progression has been 
extensively studied. The overexpression of either of the two factors in tumors results in a 
significantly amplified tumor-associated lymphatic vessel growth (mainly at the tumor margin) 
and increased occurrence of lymph node metastasis.  The lymphangiogenic growth factors 
along with increasing vessel density, also enlarge and dilate vessel size. VEGF 2 receptor is 
important in this process, while VEGF 3 receptor is involved in endothelial cell sprouting.[195-
200] 
 
 
 
 
 
 
Fig 2. In situ and invasive cancer 
1.4.5 Cytomegalovirus and cancer 
Emerging evidence indicate that cytomegalovirus (CMV), which is not considered as an 
oncogenic virus, is highly present in several types of cancer. CMV belongs to the family 
Herpesviridae and the subclass Betaherpesviridae. CMV remains latent in the body for the life 
time of its host after a primary infection without causing any clinical disease in healthy 
individuals. It can reactivate from time to time, but is kept under control by the immune system. 
However, in immunocompromised individuals CMV infection may be life threatening; it 
causes major morbidity and mortality in stem cell and organ transplant patients as well as in 
AIDS patients. It is also a common cause of birth defects in children who suffer from a 
congenital infection.  
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Emerging evidence suggest that the virus is detected in high prevalence in tumors of different 
origin. Over 90% of glioblastoma, neuroblastoma, medullblastoma, colon, breast and prostate 
cancers are positive for CMV proteins and nucleic acids. The virus is also detected in lymph 
node and brain metastases of colon and breast cancer patients. However, it is rarely found in 
healthy tissue surrounding the primary tumor.  
     Although HCMV is found in lymphnode and distant metastases, the potential virus related     
mechanisms of metastasis promotion are not understood [201, 202] 
1.4.5.1 HCMV Structure  
HCMV is the largest and the most complex amongst the herpesviruses. Its genome is 
approximately 235 kbp and consists of 252 open reading frames which encodes for 180 
proteins. Until recently, it was believed that CMV encodes about 180 proteins which are 
involved in various biological events that affect the infected cells physiological function. A 
recent study proposes that this number may surpass 750 proteins, most of which are not vital 
for virus replication and alternately find implications in different pathologies. Only 50 proteins 
are essential for viral replication. This indicates that HCMV could in fact be much more 
complex than previously believed.[203-205] 
It consists of an inner core of double stranded DNA surrounded by a nucleocapsid along with 
a thick layer of tegument protein surrounded a lipid bilayer. HCMV has a typical virion 
structure of about 200-300 nm in size. The nucleocapsid 125 nm in diameter, which is 
surrounded by a tegument layer and a lipid envelope. The lipid bilayer consists several viral 
glycoproteins and glycoprotein complexes that serve important functions in viral entry. The 
capsid is comprised of five core proteins, namely major capsid protein, minor capsid protein, 
triplexes, smallest capsid protein and portal protein  and minor capsid binding protein. [205] 
During the capsid assembly process during viral replication, three diverse types of capsids are 
observed; - A capsids with only a capsid shell, B capsids with a capsid shell and assembled 
proteins and and a mature C capsid with a capsid shell containing the viral DNA genome. The 
third type is the only form that has completed maturation. The first two types of capsids do not 
contain viral DNA, and hence fail to form mature infectious virions. Alternatively, A or B 
capsids proceeed to envelopment and form a type of virus particles called defective virus 
particle like or noninfectious virus particles. CMV infected cells also produce dense bodies that 
do not contain capsids, they only contain proteins, [206] 
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The nucleocapsid is covered by a thick layer of viral derived proteins called the tegument. The 
tegument also contains a selection of viral and cellular RNAs. Most of the tegument proteins 
are phosphorylated, which possibly helps facilitate stable association and incorporation into the 
virion compartment.[207] The most abundant HCMV tegument proteins are pp65, pp71 and 
pp150 and they play important roles in un-coating the particle during entry and during virion 
assembly.  
In addition to this they also play important functional roles through modulation of the host 
immune     response to infection, thus providing a favorable intracellular environment for viral 
replication.[208-210] 
Every herpesvirus expresses gB and gH/gL proteins that are essential for viral entry. Studies 
show that herpesvirus gB molecules are fusion proteins and they are associated with liposomes. 
Like for other herpesviruses, HCMV gB and gH/gL are important for virus entry. Along with 
the above proteins, the phospholipid envelope also contains the UL128-131 complex, referred 
to as the pentameric complex. These glycoproteins, together, play important roles in virus entry 
into host cells, cell-to-cell spread, and virion maturation [211-215].  
1.4.5.2 Entry and Assembly  
Different steps are required for initiation of viral entry. and are differently utilized in different 
cell types. HCMV initiates infection by binding to cell surface heparan sulfate proteoglycans 
(HSPGs) and this binding is one of the relatively conserved features of herpesvirus entry 
pathways. HCMV binding to HSPGs is implied to play a vital role in initial stage of entry. This 
is thought to enhance the attachment to subsequent receptors in a cascade that ultimately leads 
to fusion [216, 217]. In fibroblasts, the virus attaches to specific cellular receptors and 
subsequently the viral envelope fuses with the cell membrane followed by the release of 
nucleocapsids into the cytoplasm. Alternatively, the virus is taken up by receptor mediated 
endocytosis and fusion of the virus envelope with the endosomal membrane occurs in the 
cytoplasm. 
HCMV can adhere to and penetrate both permissive and non-permissive cell types, but fruitful 
replication is detected in a very limited range of human cells. This shows that viral gene 
expression is restricted due to a post penetration block in non-permissive cells [218] 
Once the virus fuses with the cell, the nucleocapsid is released in the cytoplasm. After the 
nucleocapsid is translocated into the nucleus an interaction with nuclear pores occur followed 
by release of the viral genome into the nucleus.  
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Following insertion, the viral genes are expressed in a thorough manner. Three classes of 
proteins are expressed; the Immediate Early (IE), followed by Early (E) and Late (LA) 
proteins. The IE proteins are the first to be expressed (within 3-4 hours) followed by the other 
E and L proteins. Once the IE proteins are expressed, these proteins help in regulating the 
expression of the other genes, acting either as auto stimulators or transactivators. The E and L 
proteins are required for setting up the structure of the virus particle along with coding for 
other proteins that modulate host cell functions.[208] The whole infection cycle takes 48-72 
hours.[208] 
Two major gene products, IE-72 and IE-86, are responsible for regulating the expression of 
most the HCMV genes. IE-72 is unessential for virus growth whereas IE-86 is required for 
regulating its DNA replication. Both have an effect on cell cycle regulation through interactions 
with tumor suppressor proteins, promotion of cell-cycle progression, initiation of DNA 
synthesis, telomerase activity and apoptosis inhibition [219] 
Post replication, the viral DNA is packaged into the synthesized capsid and exported through 
various cellular compartments. Here it acquires its remaining structural components (the 
tegument and envelope). Virus budding takes place in Golgi-derived intracellular 
vacuoles.[220] The mature virions are consequently transported to the plasma membrane, 
where they are released following fusion of the transport vesicle and the plasma membrane.   
1.4.5.3 HCMV latency and reactivation 
A property common to all herpesviruses is their ability to establish lifelong persistence in their 
host following primary infection, but the exact sites and the mechanisms controlling this 
process is not clearly understood. Analysis of the peripheral blood show that monocytes and 
CD34 + progenitor cells are the sites that carry the latent virus in vivo.[221] In these cells, due 
to the combined effect of a lack of viral activators, the presence of latency-associated repressors 
and the dominance of cellular transcriptional repressors of the major immediate early promoter 
gene (MIEP), the chromatin around the viral MIEP becomes heavily repressive thus 
suppressing lytic transcription and maintaining latent infection. Another crucial factor playing 
a role during latency is GATA-2. This transcription factor aids in latency persistence of HCMV 
in myeloid cells. Subsequently, a pathway of interactions seems to occur during latency. This 
results  in the targeting of cellular hsa-miR92a which in turn, up-regulates cellular GATA-2 
expression [222] leading to a downstream influence on latency-associated LUNA gene 
expression [223] eventually warranting  UL138 expression[224]. Studies have shown that 
expression of the viral transcript UL138 is required for viral latency establishment and 
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maintenance. This occurs through down regulation of multidrug resistance–associated protein- 
(MRP1) reduced cellular leukotriene C4 export, which possibly inhibits the migration of 
infected DCs to draining lymph nodes thus impairing HCMV-specific immune response 
generation. [225] The mechanism of HCMV reactivation is poorly understood but is known to 
be triggered by inflammatory cytokines and differentiation of monocytes into macrophages or 
dendritic cells [226] 
 Efforts have been made to detect specific latency-associated transcripts in experimental 
models. It is known that HCMV encodes a viral interleukin (IL)-10 homologue (UL111a; 
cmvIL-10) in HCMV infected cells which is a well-known immunosuppressive cytokine. 
During latency, this protein’s transcript undergoes alternative splicing, resulting in the 
expression of latency-associated cmvIL-10. This helps the virus to avoid recognition by 
immune system and clearance during latency.[227] 
1.4.5.4 CMV and angiogenesis  
HCMV has been shown to induce angiogenesis, which could be significant for HCMV-
enhanced tumor formation. HCMV infects different cell types that are involved in 
angiogenesis, such as endothelial cells, fibroblasts macrophages and smooth muscle cells. It 
also promotes angiogenesis through direct and indirect mechanisms. Additionally, infection at 
sites close to the vessel might promote angiogenesis by releasing angiogenic factors. CMV 
infection of fibroblasts and EC promotes the synthesis and release of several angiogenic factors 
that stimulate several stages of angiogenesis. It is known that VEGF is essential for 
angiogenesis to occur. HCMV drives the production of VEGF through US28 induced COX-2 
expression and NF-kB activation. When an angiogenic stimulus occurs, EC’s respond by 
attracting and binding leukocytes and platelets resulting in production and release of various 
pro-angiogenic factors. It has been shown that CMV infection modifies the types and quantities 
of these factors.  It is called the HCMV secretome. The main components of this secretome are 
chemokines and cytokines such as CCL 3, 5 7 and CCL 20, CXCL 5 and 16, IL 6, receptors 
ICAM 1. Also, growth factors such as TGF beta, HGF and ECM modifiers like MMP’s are 
involved.[228-232] 
Infection is initiated when HCMV binds to the cell through entry receptors and then enters the 
cells through fusion at the plasma membrane or via receptor mediated endocutosis (see above). 
Viral proteins that are present in the envelope can remain on the cell surface after entry and 
activate the cell. For example, US28 remins on the cell surface after entry and G protein 
mediated signaling pathways. This further activates transcription factors NF-kB, NFAT, TCF 
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and LEF. The activity of US28 can further be modulated by chemokines such as CCL2, 5 and 
CX3CL1. Once the transcription factors are activated, they promote cell proliferation through 
cyclin D1 angiogenesis through VEGF.[233] US28 induces secretion of cytokines and growth 
factors such as VEGF , IL-6, which in turn act on their related receptors and induce and 
autocrine cellular response and activation of STAT-3. This also increases cellular responses of 
the neighboring cells.  
For example, US28 induces prostaglandin production and activates cognate receptors to induce 
production of VEGF, thus promoting angiogenesis. [234, 235] 
1.4.5.5 Tumor dissemination  
HCMV is suggested to play a role in tumor dissemination. For example, HCMV infection of 
neuroblastoma cells leads to enhanced tumor cell adhesion to endothelial cells resulting in the 
disruption of EC monolayer integrity. This leads to enhanced neuroblastoma invasiveness and 
higher trans-endothelial migration.in in vitro models[236] [237]. Studies also show the role of 
HCMV in EMT related to metastasis. A study by Shimamura et al examined the role of HCMV 
in the induction of TGF-β and its role in EMT. Upon infecting human renal tubular epithelial 
cells invitro it was observed that these cells undergo morphologicl and transcriptional changes 
closely related to EMT. Also, TGF-β and MMP-2 expression was induced and could further 
fuel EMT process. HCMV IE proteins was suggested to control this process as their 
overexpression mimic these effects and as targeting late gene expression did not inhibit these 
changes. 
Several factors involved in EMT are similarly modulated by HCMV. This includes induced 
production of growth factors and induced signaling pathways. Further studies are required to 
comprehend the role of HCMV infection in EMT transition and metastasis formation.  
In this thesis through study 3 we investigated the role of murine cmv in colon cancer metastasis.  
1.5 CANCER IMMUNOLOGY  
 Cancer cells that exist in the primary site of a tumor are immune protected, cells which exit this 
site and enter circulation are compromised and vulnerable to immune surveillance, hence the 
survival of these cells are essential for metastatic spread. Thus, immune escape mechanisms 
are required for cell survival. [179] 
 Immune escape mechanisms or immunoediting are important aspects for cancer cell survival. 
Immunoediting is a process, that comprises of immune surveillance and tumor progression.  
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It consists of three phases leading to cancer progression. The first phase is called elimination, 
when neoplastic cells are contained and destroyed by innate and adaptive immune cells.  
The second phase equilibrium is attained following an escape of the neoplastic cells escape 
from elimination and their interactions with immune cells reach an equilibrium with the 
immune system exerting a constant pressure.  Hence even though the immune system wants to 
prevent the cells from progressing, it unwillingly contributes to tumor cell survival by selective 
clonal selection. This leads to the third stage, the escape phase, where the colonies that survived 
the previous phases, gain the ability to grow in an immune competent environment.[238-240] 
Tumors that escape immune evasion acquire resistance to immune factors, for example 
interferon gamma. Insensitivity to interferon gamma, enhances tumor resistance to immune 
attacks. Also, tumors evade immune cells either by shedding or restricting presentation of their 
ligands for recognition by NK cells and cytotoxic T lymphocytes.  
  The tumors also downregulate other factors that elicit a tumor-immune response, for example 
pro inflammatory cytokines and chemokines. [241-246] 
1.5.1 Immune surveillance  
NK cells and macrophages are the most well studied cells with respect to tumor suppression 
and surveillance. NK cells are an important part of the innate immune system and they play a 
major role in defense against tumors and viruses. The interactions of these cells with tumors 
are mediated by a network of receptors and ligands including the major histocompatibility 
complex (MHC) class 1- related inhibitory molecules. Inhibition of NK cell signaling leads to 
tumor lysis through cytolytic granules release and apoptosis induction. These effects of the NK 
cells are decreased in CTC positive patients with metastatic colon and breast cancer compared 
to CTC negative patients. [246-249] 
Macrophages, along with NK cells play an important role in controlling metastatic progression. 
Macrophages are vital for antibody dependent phagocytosis of tumors. This process is mostly 
governed by macrophages in the liver. A study by Denève et al showed comparisons of CTC 
counts between peripheral and mesenteric blood samples in patients with colorectal cancer 
confirmed that a considerable proportion of the viable CTC population seem to be filtered and 
trapped in the liver. Thus, these findings highlight the importance of the liver 
microenvironment in mediating the outcome of interactions between tumor cells and immune 
cells. This often promotes tumor-cell death and sometimes facilitates disseminated tumor cells 
(DTC) survival and growth.[250-252] 
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1.5.1.1 Immunoediting  
The immunological elimination of tumor antigen is driven by T- cell recognition. Studies have 
validated this. A study on genetic mapping using a mouse model of a highly immunogencic 
and unedited sarcoma to determine its mutational landscape demonstrated that cancer 
immunoediting is the result of a T-cell-dependent immunoselection process which leads to 
extension of tumor cell clones that lack immunodominant rejection antigens displaying reduced 
immunogenicity. A study by DuPage et al reached a similar conclusion. Studies also show the 
involvement of innate immunity in the immunoediting process. NK cells apparently activated 
by local amplification of endogenous IL-12 can produce IFN-γ that in succession induces 
activation of M1 macrophages. These act as significant effectors of cancer immunoediting. 
Thus, these results show that the host’s immunocompetence level plays a vital role in the extent 
to which a tumor undergoes immunoediting.[253, 254]  
1.5.1.2  Elimination 
Many reviews have described and summarized the mechanisms that take place in the 
elimination phase. The role of host recognition molecules such as NKG2D; IFN-γ, perforin, 
effector molecules like Fas/FasL, and TRAIL; and an intact lymphocyte compartment in 
protective anti-tumor immunity, are well known. Both type I (IFN-α/β) and type II interferons 
(IFN-γ) are essential for the growth of anti-tumor immune responses but play diverse role in 
cancer immunoediting processes. While IFN-γ targets both tumor cells and hematopoietic 
tumor cells, IFN- α/β acts primarily on host cells. Recently, two studies showed that type I 
IFNs are mandatory for initiating early anti-tumor response and act on CD8α/CD103+ DCs to 
augment cross-presentation of tumor antigens to CD8+ T cells. Type I IFN sensitivity in 
macrophages, NK cells and granulocytes, all of which express type I IFN receptors was not 
essential for tumor rejection.[255, 256] 
1.5.1.3 Equilibrium  
Adaptive Th1-like immunity also plays an important role in the equilibrium phase and studies 
have described this process. For instance, a study using an immune-mediated dormancy model 
of fibrosarcoma and another study using the same mouse model of MCA- induced 
fibrosarcoma and p53 mutant tumors showed that immune-mediated tumor latency may be a 
very lengthy process and related to the balance of IL-12 promoting elimination, and IL-23 
(sharing the common subunit IL-12 (p40)) sustains tumors in equilibrium and promotes 
persistence. Apart from a trivial tumor-promoting role for IL-10 various other pathways (e.g. 
IL-4, IL-17A, TNF, IFN-αβ) were shown to be nonessential for this phase.[242, 257] 
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Tumors that escape go on to metastasize. Specific mechanisms involved in this process are 
discussed below. 
1.5.2 Immune evasion mechanism  
As mentioned before, CTCs leaving the immunosuppressive primary tumor microenvironment 
are exposed to the active immune surveillance mechanisms. In addition, the possibility that 
CTCs will be lysed by tumor-specific immune cells increases significantly outside the 
immunosuppressive reserve of the tumor since peripheral immune cells are more abundant than 
CTCs. Hence the circulatory system is considered a hostile environment for cancer cells. 
Primary tumors are predicted to shed thousands of cells into the bloodstream every day, but 
evidently only a very small percentage develop the ability to grow into distant metastases which 
supports this assumption.  
However, studies have identified new pathways through which CTCs might evade or survive 
encounters with immune cells. The most established mechanism of tumor evasion includes the 
ones previously described (NK cells and macrophages), CD 47 signaling, FAS/FASL signaling 
and hypoxia induced apoptosis.[258] 
1.5.2.1 MHC molecules and NK -cell ligands 
MHC I molecules that expressed on the surface of basically all nucleated cells present peptide 
epitopes that are processed from intracellular proteins for examination by T cells. Thus, 
presentation of tumor-associated antigens (TAAs) to T-cell receptors (TCR) in the context of 
MHC I molecules is crucial for initiation of an adaptive CD8+ CTL response. Hence, 
downregulation or entire loss of MHC I expression at the cell surface is a mechanism used by 
tumor cells to 'hide' from CTLs and thus avoid death. As a standby to counteract this 
mechanism, NK cells become activated when MHC I molecules are under expressed or absent 
and they are activated by the missing ‘self-hypothesis’. Therefore, to escape both NK-mediated 
and CTL-mediated cytotoxicity, CTCs have to find a way to present MHC I molecules without 
presenting TAAs. or avoid NK cell activation [259-262] 
Cytokeratin 8 (CK8), along with its heterodimeric partners CK18 and CK19, have been shown 
to inhibit MHC I interactions with TCRs on CD8+ CTLs. Overexpression of these cytokeratins 
has long been detected in malignant tissues. This mechanism demonstrates how cancer cells 
develop new methods of immune evasion, and that interfering with MHC-mediated antigen 
presentation seem like a critical approach to escape immune recognition.[263, 264] 
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1.5.2.2 FAS/FASL induced apoptosis 
This apoptotic pathway is highly important to immune evasion. The transmembrane receptor 
FAS can initiate apoptosis, and activation of this receptor on T cells via binding to FASL is a 
suggested mechanism of tumor-mediated immunosuppression in several malignancies. For 
example, histopathological analyses have shown that FASL is upregulated in metastases 
compared to the primary tumor in patients with melanoma or colorectal cancer. [286-287] Also, 
in patients with breast cancer, upregulation of FASL has been associated with increased 
apoptosis of T cells. Hence FASL expression on tumor cells may actively induce apoptosis in 
immune cells. Vice versa, tumor cells that express FAS will most likely be vulnerable to 
apoptosis evoked by tumor-specific immune cells, which can also express FASL. Hence, 
instantaneous loss or downregulation of FAS and upregulation of FASL on tumor cells might 
add to tumor evasion strategies of immune-mediated cytolysis and increase the probability for 
metastatic progression.[265-269] 
1.5.2.3 CD47-mediated signaling 
Several studies by Irving Weissman and colleagues have emphasized the role of the leukocyte 
surface antigen CD47 in cancer, mostly, in cancer-cell evasion of phagocytic clearance. CD47 
binds to its ligand signal-regulatory protein α (SIRPα, also known as macrophage fusion 
receptor), expressed on macrophages and dendritic cells, subsequently inhibiting phagocytosis 
by these cell types. Therefore, upregulation of CD47, an antiphagocytic 'don't eat me' signal, 
might confer CTCs with a non-immunogenic profile by allowing them to escape the 
consequences of cell-damage-induced upregulation of pro-phagocytic signals and, thus, the 
immune sequelae evoked after CTC recognition in the context of adaptive immunity. Steinert et 
al have assessed the gene-expression profiles of primary tumors and CTCs from patients with 
colorectal cancer. Notably, CD47 was the only gene upregulated in CTCs versus the matched 
primary tumors, signifying a survival advantage conferred by CD47 expression for peripheral 
blood CTCs. Therefore, these findings along with others propose that CD47 is part of a 
potential metastasis-initiator cell signature, but functional analysis is required to describe the 
exact role of CD47 expression on CTCs.[270-275] 
1.5.2.4 Hypoxia mediated immune escape 
Various genes are expressed during EMT, in cancer-stem cells, or in response to hypoxia. They 
have been shown to be upregulated in CTCs, and many of the encoded proteins can control the 
immune response. Specific metabolic and molecular changes enable DTCs to adapt to and 
survive in a microenvironment with a lower oxygen concentration. Evidence investigating HIF-
1αexpression in CTC’s and functional studies of DTC’s in the bone marrow of patients with 
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lung, breast and prostate cancer show that many CTCs and DTCs exhibit a hypoxia-associated 
phenotype, and that these cells can adapt well to hypoxic condition.  For example, upon hypoxic 
stress, glucose-regulated protein 78 (Grp78) is upregulated in cell lines established from the 
bone marrow of patients with cancer, and expression of Grp78 is linked with mesenchymal 
characteristics and poorly differentiated primary breast and lung tumors. Ongoing studies are 
investigating if adaptation to hypoxia also promotes CTC and/or DTC evasion of immune cells. 
Nonetheless, the hypoxia-resistant phenotype of DTCs has implications for immunotherapeutic 
strategies.[276-278] 
1.5.2.5 Metastasis promotion by immune cells 
Studies show that metastasis can be supported by immune cells. Immune cells can, hence, be 
regarded as both protagonists and antagonists in the metastatic process.[279-281] 
1.5.2.6 Promotion of CTC seeding 
Preliminary studies of CTCs have established a positive correlation between an acute 
inflammatory condition and formation of metastasis in the target organ of metastatic spread.  
For instance, Taranova et al using an allergic pulmonary inflammation model indicated that for 
CTCs to extravasate and form tumor filiae. They take advantage of the augmented vascular 
permeability and expression of adhesion molecules at the site of metastasis formation. The 
study also demonstrated that for CTC’s to metastasize to the lung, they required the presence 
of CD4+ T cells at the site of metastasis. Along these lines, data from a murine colorectal cancer 
model indicated a positive correlation between CTCs and serum levels of IL-17A, a 
proinflammatory cytokine. In addition, the presence of IL-17A augmented tumor-cell motility. 
This occured by triggering MMP-9 expression in CTCs, hence possibly supporting CTC 
mobilization and extravasation.[282, 283] 
Put together, escape from and variations in peripheral immune responses outside the local 
tumor milieu, are critical steps in metastases development.  
1.6 C/EBPΒ 
C/EBPβ is a protein belonging to the C/EBP family. The family overall, consists of six 
transcription factors from C/EBPα to C/EBPζ and is characterized by a basic leucine zipper at 
the C-terminus required for binding and dimerization. The family of proteins regulate different 
gene expressions taking part in cell differentiation, proliferation inflammation and metabolism. 
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 C/EBPβ can form heterodimers with members of the C/EBP family, such as C/EBPα, C/EBPγ 
and C/EBPδ, along with other transcription factors such as Sp1 or CREB1.  C/EBPβ can also 
bind as a homodimer to some DNA regulatory regions thereby controlling the expressions of 
various target genes.[284, 285] 
The C/EBPβ gene encodes three different protein isoforms: LAP1, LAP2 (liver- enriched 
activator proteins) and LIP (liver-enriched inhibitor protein), which are expressed depending 
on differential use of specific in-frame translation sites. [286]LAP1 and LAP2 are 
transcriptional activators, and LIP is their inhibitor. The functions of all C/EBPβ isoforms are 
still under investigation and largely dependent on the cellular context.[287] 
The mammalian target of rapamycin (mTOR) pathway, tightly regulates the production of 
C/EBPβ isoform. In this pathway, mTOR activation stimulates LIP expression and its 
inhibition enhances LAP production. Moreover, the truncated LIP isoform forms by partial 
proteolysis of longer C/EBPβ isoforms.[288] [289] All the isoforms contain C-terminal bZIP 
domain and LAP1 and LAP2 maintain N-terminal transactivation and chromatin remodelling 
domains. The ratio of C/EBPβ isoforms is believed to determine cell fate.[290, 291] 
As a transcription factor, C/EBPβ interacts with several target genes and is required for a 
number of biological processes, such as, granulopoiesis, adipogenesis, muscle repair, 
embryogenesis, and osteoporosis. [292]It is involved in controlling autophagy, cell growth and 
antibacterial defence, along with regulating insulin level and insulin receptors expression [293-
295]C/EBPβ is also regulates  multiple genes responsible for immune and inflammatory 
response. Evidence show its binding to cytokine coding genes such as IL-4, IL-6, IL-5 and 
TNFα. It is also responsible for activation and terminal differentiation of macrophages.[296, 
297] Since C/EBPβ expression plays a role in astrocyte inflammatory response, its expression 
is altered in various neurological disorders including Alzheimer’s disease, Parkinson’s disease  
and HIV-1-associated dementia[298, 299] 
Our studies emphasize the involvement of C/EBPβ in breast cancer. In breast cancer, the 
C/EBPβ gene is usually not mutated. A few rare mutations that have been found are questioned 
regarding their contribution to epithelial tumors. However, C/EBPβ expression might be 
augmented in a small subgroup of breast neoplasia, described as lobular carcinoma in situ. 
Elevated levels of C/EBPβ mRNA are however also linked to metastatic breast cancer, higher 
tumor grade, and overall worse prognosis.[300-304] 
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1.6.1 Development of mammary gland  
Both LAP1 and LAP2 are expressed in non-malignant, human mammary epithelial cells, as 
well as in breast tumors. LAP1 is expressed in normal mammary cells, while LAP2 is found 
only in dividing cells, normal and neoplastic. In vitroand in vivo studies have showed potential 
and substantial role of C/EBPβ isoforms in mammary gland development and breast 
cancer.[305-307] For example, in vitrostudies show that LIP overexpression in mouse 
fibroblasts or mammary epithelial cells causes increased proliferation, foci formation and lack 
of contact inhibition. Moreover, transgenic mice with LIP overexpression in the mammary 
gland develop alveolar hyperplasia, invasive and noninvasive carcinomas and high grade 
mammary intraepithelial neoplasias. Other studies, using C/EBPβ-/- mice, revealed that 
C/EBPβ is vital for ductal morphogenesis, functional differentiation in the murine mammary 
gland and epithelial cell proliferation.[308-310] 
In this thesis, through study 4, we investigated the role of C/EBPβ in breast cancer metastasis. 
1.7 CANCER PROGRESSION AND EMT  
Epithelial-Mesenchymal transition (EMT) is a process by which epithelial cells transform into 
mesenchymal cells. This occurs due to the loss of cell polarity and cell-to-cell adhesion 
molecules. This process is important in wound healing and embryogenesis. The reverse 
process, mesenchymal epithelial transition (MET) is also essential for various organ 
developments. It is also known to be involved in cancer progression and metastasis formation. 
Epithelial cells are single or multilayer cells with various functions.  
They depict apical-basal polarity and through specialized intracellular junctions, adhere and 
communicate with adjacent cells. Their position and interaction of the basement membrane 
proteins with integrins help define their physiology. The transition of the cells follows certain 
hallmarks and patterns. The plasticity of the epithelial phenotype enables cell transition through 
multiple EMT and MET rounds. 
EMT increases the invasive phenotype of the cancer cells. They lose their expression cell-cell 
adhesion molecule, E-cadherin and the attachment to the basement membrane. TGF-beta  is a 
major factor that induces this property in tumor cells when it acts on activated RAS- expressing  
cells, leading to  EMT and inhibition of  apoptosis.[311] Evidence suggests that activated 
platelets have a direct contribution to the invasive phenotype of the cancer cells at the primary 
tumor site. In breast carcinoma, higher levels of TGF beta 1 and TBRII can be found  [312] 
The expression of TGF- beta varies with different cell types, thus understanding and 
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quantifying the process is difficult.[311, 313, 314] In this context it is interesting to note that 
CMV induces production of TGF-beta and an EMT like process [315] 
There are three types of EMT based on the physiological context. Type 1 EMT is the 
differentiation of epithelial cells to mesenchymal cells with no prior history of transition. Type 
2 EMT is a process where cells have already undergone transition followed by reversion and 
initiation of a new EMT.  Type 3 EMT leads to cancer progression and cancer stem cell 
properties. Similarly, following dissemination, cancer cells revert to epithelial cells through 
MET and secondary carcinomas are generated having similar phenotypes. A pro invasive 
function of cancer cells is attributed to the expression of avβ3 integrin that is increased due to 
EMT.[316, 317] 
Various transcription factors like SNAIL, TWIST and ZEB have prominent roles in EMT and 
cancer progression. They have different profiles and functions based on the cell type in which 
they are expressed. TWIST 1 down regulates epithelial gene expression and enhances 
expression of mesenchymal genes. SNAIL 1 and 2 has a similar role. Other transcription factors 
such as forkhead box (FOX) and GATA family and growth factors such as VEGF and FGF are 
also involved in EMT regulation.[311, 313] 
1.8 RED BLOOD CELL DISTRIBUTION WIDTH (RDW)- A PROGNOSTIC 
FACTOR FOR PATIENTS WITH CARDIAC DISEASES AND CANCER 
Red blood cell distribution width is the uneven size of the red blood cells with a higher RDW 
than normal. It is usually denoted in combination with red blood cell corpuscular volume in 
diagnosis of chronic inflammatory status in the body. Anisocytosis is a RDW higher than the 
normal range and is commonly found in anemia and other blood disorders. 
1.8.1 Red blood cell distribution width and CVD 
Besides many blood disorders, RWD levels are associated with acute and chronic 
cardiovascular diseases such as peripheral artery disease, acute coronary syndrome and 
ischemic cerebrovascular disease.[318] Many studies have shown an interesting relationship 
between carotid atherosclerosis or stroke[319, 320]. Wen et al. observed an intricate connection 
between high RDW and advanced subclinical atherosclerosis such as an upsurge in intimal -
medial thickness and evidence of carotid plaques.[321] Sánchez-Chaparro et al. showed that 
high RDW is associated with metabolic syndrome (MetS) a condition that encompasses various 
risk factors for cardiovascular diseases.[322] 
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A reason for a consistent increase in RDW in CVD is attributed to active stimulation of 
erythropoiesis by erythropoietin (EPO) a hormone, secreted during hypoxic conditions. This 
promotes the release of enflamed RBCs from the bone marrow. Another hypothesis for high 
RBC could be due to a minor reduction in RBC turnover. Since the size of RBCs gradually 
decreases with cell ageing, a diminished rate of RBC turnover would allow minor cells to 
continue longer in circulation.[323] 
1.8.2  Red blood cell distribution width and cancer- A risk factor for death 
Recent studies indicate that anisocytosis is a prognostic indicator of death in various 
atherosclerotic related diseases. It is considered as a marker for inflammation in various 
diseases including cancer. Research shows that cancer anemia and high RDW have a 
connection, both are dependent on VEGEF A. [324-327] 
Cancer is attributed to increased inflammation and studies show that RDW is increased in 
damaged cardio metabolic functions and active inflammation. [327-328] Very limited studies 
show that solid tumors activate inflammation. 
Two studies reported the use of RDW as an added parameter in detection of anemia in colon 
cancer patients. Spell et al showed that the value of RDW could be a useful marker with 14, 
8% cut-off value, 72% sensitivity and 69% specificity to differentiate between malignant and 
benign reasons leading biliary obstruction. Similarly, Ays et al reported that RDW increased 
in malignant lesions compared with benign breast tissue but no cut off value was suggested. 
Their study concluded that RDW is an interesting parameter and increases in colon cancer 
before anemia develops. [324-327] In this thesis through study 2 we investigated the role of 
anisocytosis measured by red distribution width  
 
1.9 CVD CO-MORBIDITY IN CANCER  
Post-secondary malignancies, CVD is the foremost cause of morbidity and mortality among 
cancer survivors[328]. CVD risk factors are predominant in cancer patients. A study by 
Mertens et al showed that among childhood cancer survivors, cardiovascular events are the 
principal non-malignant cause of death. It is responsible for a higher risk of death, about 7-fold 
high, among these patients when compared to their controls. Side effects of cardiotoxic cancer 
therapy is thought to be the fundamental cause for this observation. [329]Alternatively, a study 
by Enright and Krzyzanowska reiterated the necessity for precise individualized cardiovascular 
disease prevention program for cancer survivors. They showed that the subpar control provided 
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for traditional measure of risk factors like cholesterol monitoring and blood pressure among 
survivors. [330] 
Recent developments indicate an increasing interest in a theory for development of CVD in 
cancer patients. This is the multiple-hit hypothesis. Jones et al. first defined this in 2007. He 
proposed that CVD development in cancer patients takes place when they are exposed to a 
series of chronological or simultaneous events that together make them more susceptible to 
cardiovascular reserves and ultimately result in death.  Another risk factor for development of 
CVD is psychological distress in non-cancer populations. Put together the multiple-hit 
hypothesis has been well conceived.[253] 
Cancer treatments include chemo, radiation, immuno or hormone targeted therapies or a 
combination of these. Some amongst them are cardiotoxic. For instance, for lymphoma or 
breast cancer treatments, chemotherapy with anthracyclines as well as radiation therapy to the 
chest are cardiotoxic. These can lead to a reduction in cardiovascular reserves and eventually 
different sets of CVDs ranging from benign to possibly fatal conditions. [331]CVDs associated 
with cancer treatment can occur within a few days, months or years. They include arrhythmias, 
myocardial infarction, thrombosis, congestive heart failure and cardiomyopathy.[332, 333] 
Lifestyle factors also contribute to process. Due to cancer treatments patients might develop an 
unhealthy life style which includes physical inactivity and weight loss. This might lead to a 
reduction of CV reserves and augments CVD risk and death.  
Psychological distress another important risk factor, whose presence is a bad for health 
outcome of patients. Independent of traditional biomedical risk factors, depression symptoms, 
fatigue and anxiety have shown to forecast CVD onset and prognosis in patients with 
established CVD. [334, 335]This was validated based on a meta-analysis of 20 studies, which 
showed the value of anxiety prediction for coronary heart disease occurrence in formerly 
healthy individuals. It showed that there is 26% higher risk of coronary heart disease 
development and a 48% increase in risk of cardiac death among anxious individuals.[336]    
Thus, research on an adapted multiple-hit hypothesis for CVD development among cancer 
patients could contribute to advances regarding their care. An immediate necessity for CVD 
preventive procedures to reduce the delayed adverse effects of cancer therapies such as 
radiation and chemotherapy and early intervention could possibly help improve CVD’s risk 
profiles.[337]   
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1.10 CVD AND CANCER INDUCED THROMBOSIS  
The endothelium plays an essential role in the hemostatic system. Depending on precise 
tissue requirements and local stresses, endothelial cells can induce either antithrombotic or 
pro-thrombotic events.  An efficient endothelium is crucial to maintain hemostasis and avoid 
thrombosis.  Normal endothelial cells express antiplatelet and anticoagulant agents. They 
avert platelet aggregation and fibrin formation, respectively by releasing pro-fibrinolytic 
agents that initiate fibrinolysis to destroy the clot. During endothelial dysfunction, endothelial 
cells activate fibrin formation, along with platelet adhesion and aggregation. Thrombosis is 
the formation of a clot within a blood vessel resulting in a reduction of blood flow to distal 
tissue and organs. This limits the delivery of nutrients and oxygen and results in localized 
tissue and organ necrosis. Large occlusive clots (thrombi) break off and embolize forming 
secondary thrombi in distal locations. This is known as thromboembolism and can lead to 
various local or chronic disorders. For instance, acute arterial thrombosis is activated when an  
atherosclerotic plaque ruptures, and is the major cause of myocardial infarction and 
stroke[338]. Likewise, venous thromboembolism can be activated by distressed blood flow, 
endothelial activation, hypercoagulable conditions, such as procoagulant changes in the 
blood. Similarly, the process is also induced in cancer. A surface receptor thrombomodulin, is 
known to be involved in cancer development, coagulation and inflammation. The receptor is 
present plentifully in several types of endothelial cells but is poorly expressed or absent in 
brain microvascular and liver sinusoidal endothelial cells. Studies have also shown that the 
expression of tissue factor induces tumor angiogenesis in colon and breast cancer models 
through TF-fVIIa-dependent PAR-2 activation. This induces the expression of VEGF, IL-8, 
MMP-7, and CXCL-1.[339] 
In this thesis through study 2 we investigated the role anisocytosis in determining blood flow 
along the vessel wall, its interactions, culminating in thrombosis in different vascular diseases 
and cancer. 
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2 AIMS OF THE THESIS 
The general aim of the thesis was to study the implications of a damaged endothelium in 
pathologies related to vascular disease and cancer metastases 
The specific aims were: 
• To  identify subtypes of bone marrow cells contributing towards intimal hyperplasia and 
tissue repair.  
• To investigate the role of high RDW modulation of blood fluid dynamics related to 
CVD. 
• To study the role of MCMV in colon cancer development and progression. 
• To investigate C/EBPβ’s role in metastasis formation of breast cancer and its effect on 
vascular morphology. 
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3 RESULTS AND DISCUSSION 
Study 1:  
Intimal hyperplasia is the response to an injured endothelium. It is also the reason for lumen 
narrowing. This process occurs in response to transplantation, artery bypass conduits and 
post balloon angioplasty. The aim of our study was to examine the contribution of various 
sub populations of  BMCs contributing towards intima hyperplasia. We also examined if 
these cells play a key role in the process and constitute a developed intimal lesion or if they 
are involved only at the initial stages in arterial remodelling. We introduced carotid artery 
ligation in a chimeric mouse model involving bone marrow from GFP transgenic mice. 
Arterial injury was carried out in chimeric mice (C57BL/6 mice with BM from GFP transgenic 
mice) to examine if BM-derived cells migrated towards sites of arterial injury. This allowed 
for investigating the existence of green GFP-positive BM-derived cells in the injured arterial 
wall using confocal microscopy. Briefly, the left common carotid artery was exposed through 
a small midline incision in the neck. The artery was ligated close to the carotid bifurcation to 
interrupt blood flow. One-week post injury a 5-mm segment of the left carotid close to the 
suture was removed for further studies. 
 One-week post ligation, we observed GFP + BMCs at the site of the arterial injury. We also 
employed a mouse model of balloon angioplasty with a consequent delivery of BMCs with 
their distinct phenotypes to the site of injury. Here we observed BMCs at initial stages of the 
intimal formation but their number was continuously decreasing over time, they were 10 
folds lower at day 14 compared to day 1. This indicated that the BM derived cells were 
involved at the early stages of arterial healing and disappeared later potentially due to 
apoptosis or low survival rate of these cells in the vessel wall. By confocal microscopy we 
also showed that BMCs migrated to the sites of vascular injury and they inhibited the initial 
stages of intimal hyperplasia by 1.4-fold. 
Intriguingly, these cells expressed EC and SMC markers both in vitroin the BMC cell 
cultures and in vivo in the intima. This suggests that the BMCs are involved only in the 
initial stages and suggest that other cellular components apart from BMCs contribute 
towards the development of intimal lesions. 
 Asahara et al first showed EPC’s involvement in neo angiogenesis. New blood vessel 
formation in injured areas was induced by Sca-1 and CD34 positive cell populations and led 
to ischemic tissue recovery in mice models of ischemic injury. Studies also showed a 
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reendothelialization of injured vessels in a rat balloon injury model. Furthermore, it has also 
been shown that EPCs derived from the host reconstructed the endothelial layer in a model of 
vessel graft atherosclerosis.[340, 341] Put together these data support the present hypothesis 
that EPCs reside in tissue resident niches as well as in the bone marrow [342-344] and that 
they are able to reconstitute the damaged endothelium. Endothelial progenitor cells are cells 
with an exclusive ability to differentiate into functional endothelial cells. Generally 
circulating EPCs have been characterized by the expression of CD34, CD133 and the 
vascular endothelial growth factor receptor-2 (VEGFR2). Recent studies have also shown 
some CD14 +/ low myeloid subsets as functional endothelial precursors. These have 
additionally been shown as functional angiogenic cells, which contribute to endothelial repair 
and ischemic or tumor angiogenesis [341, 345, 346] 
In this thesis, we investigated the role of the endothelial constituent in BMCs contributing to 
arterial remodeling post injury. The first step was to find out which populations of BM derived 
cells were important for hyperplastic intimal formation. For this purpose, we isolated BMCs 
derived from GFP transgenic mice for diverse populations of, monocytic/macrophage origin 
(CD14), and endothelial origin (CD34, VEGFR- 2) and lymphocytic origin (CD3). These cells 
were then delivered locally at the site of an injured artery. Briefly, the right femoral artery was 
exposed up till the bifurcation through a transabdominal incision followed by placement of 
micro clamps on the lower aorta, left iliac artery, and the distal part of the right femoral artery. 
We then introduced a 2-F Fogarty balloon catheter (Baxter, Deerfield, IL) into the right femoral 
artery, which we inflated, and withdrew three times with rotation. Inflation was performed 
through the cannula and 1 ml of Ringer’s solution with free discharge through a micro incision. 
BMCs from GFP mice in RPMI medium were imbued and incubated in the freshly injured 
arterial wall of C57BL/6 or C57BL/6 Nude mice for 15 to 20 minutes and blood flow was 
reestablished upon removal of the micro clamps. Arteries were collected at 1, 2, 7 and 14 days’ 
post-surgery for further investigations. 
 From this process, we observed that the main phenotype of BM cells contributing to initial 
stage intimal formation are cells expressing markers for ECs (CD34 and VEGFR-2). 
Additionally, our results for the first time indicate that BMCs did not fuse with vascular 
SMCs. Also, BM derived cells weren’t equally distributed in the intima, but rather 
concentrated in thicker areas of the intima where they mainly expressed SMC markers. To 
show this, we cultured adventitial cells co-expressing Sca-1/CCR2 or c-kit/CCR2 in the 
presence of PDGF-BB for 7 days and then stained them for SM-α-actin. Remarkably, both 
cell phenotypes could differentiate into cells of SMC phenotype in the presence of 
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stimulating factors, such as PDGF-BB. Thus, as mentioned before, BM-derived cells are not 
a major cellular constituent of developed intimal lesion and are rather involved in early stage 
restoration and protective functions of intimal formation. 
Concluding, we propose that BM-derived cells play role in healing and are of high 
importance in the initial stages of intimal formation. We also suggest that other sources of 
vascular progenitor cells apart from bone marrow are likely the major composition of the 
developed intimal lesions. Additional studies are needed to better define the phenotype of 
BM-derived cells and their progenitors and characterize the specific function in in the injured 
vasculature. 
Study 2: 
Red blood cell distribution width (RDW) refers to the unequal size of red blood cells. RDW 
reflects the variation in size of red blood cells. RDW is generally reported as part of a 
complete blood count. [389]. An RDW higher than the normal range is termed anisocytosis. 
Anisocytosis has traditionally been used in combination with the RBC corpuscular volume, 
to diagnose chronic inflammatory status in the body [390] and is commonly related to chronic 
inflammatory diseases such as rheumatic arthritis, inflammatory bowel diseases, and cancer.  
Recent studies have demonstrated that cancer anaemia and high RDW are related and 
dependent on VEGF A [391]. Studies have also shown that high RDW is a predictor of 
death in various CVDs such as peripheral artery disease, acute coronary syndrome and 
ischemic cerebrovascular disease. A study on a large cohort of patients with stroke, 
myocardial infarction, and peripheral vascular disease and confirmed that high RDW is a 
predictor for mortality amongst these patients. [392] Also, anisocytosis has been described 
as a strong predictor for adverse events related to diabetes, stroke, peripheral vascular 
disease, and myocardial infarction and post clinical intervention. In our study, we 
hypothesized that RDW is not just a factor predicting for rapid progression of cardiovascular 
disease but rather a factor that directly affects blood flow and its interaction with the vessel 
wall. In healthy individuals, erythrocytes are of the same size and shape and in flowing blood 
there is a lack of direct interaction between the blood cells and vessel wall. We suggest that 
anisocytosis leads to changes in blood flow and affects the interaction between blood cells 
and the vascular endothelium. Specifically, we hypothesized that anisocytosis is directly 
connected to thrombotic episodes and to rapid development of atherosclerosis with secondary 
development of cardiac infarction and stroke due to changes in blood flow. 
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To study this in more depth, we first determined the transcriptomic background of 
atherosclerosis and its associated pathways using microarray analysis of 12 carotid plaques 
derived from 6 patients with low / normal RDW value of < 16 and from 6 patients with 
abnormal parameter value of >16. We selected and focused on 39 characteristic genes with a 
2-fold increase or decrease related to atherosclerosis.  These genes were also involved in 
cytokine/chemokine, FGF or EGF-mediated signaling pathways and connected to 
angiogenesis, blood coagulation, inflammation and cell adhesion. Our results also showed a 
positive correlation between elevated expression of FGF1, GAB1, SERPINE1, PLAT, 
PDGFD, PDGFC and high RDW value. Inversely, these genes were downregulated in 
plaques from patients with low RDW value. We also observed a decrease in the expression of 
some genes such as VCAM1, EIF5A, ICAM1, ICAM2, PPARG, which were associated with 
low RDW as compared to the high-RDW group of patients with increased expression of these 
genes. These differences were confirmed on protein level by immunohistochemistry.  
Studies show that RBCs tend to concentrate at the core during the blood flow in a vessel. In 
our study, we observed a similar distribution along the vessel radius, obtained through 
simulations using the Lattice Boltzmann method which was employed to solve for fluid flow 
consisting of 5-15 % haematocrit [393]. The haematocrit played a vital role in determining 
to what extent the RBCs migrated towards the centre leaving a region close to the channel 
wall free from RBCs, the RBC-depleted region. The haematocrit declines with increasing 
volume fraction of RBC and appears to be less dependent on bulk flow velocities. 
Thrombocytes on the other hand, behave contrary to the RBCs. They tend to aggregate at the 
vessel wall in the RBC depleted region due to radial migration because of RBC induced 
transport due to shear stress. Thrombocyte morphology is another factor that influences the 
rate at which thrombocytes migrate towards the vessel. [394, 395] 
Anisocytosis, however has never been considered a factor for the above phenomenon. One 
study pointed out that thrombocyte migration could be related to the volume excluded in the 
bulk flow for the platelets to be located in. This is because when the space between two RBCs 
are smaller than the size of the thrombocytes, the thrombocytes cannot reside in this volume. 
Accordingly, anisocytosis will influence the motion and migration of RBCs as well as 
platelets as different shapes and sizes of RBCs will lead to a different dynamic behaviour in 
the bulk flow. The flow is also affected by the size of the RBC-depleted region along with 
the frequency of collisions between RBCs and thrombocytes in the near-wall region. [396] 
[397] [398,399] 
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We next assessed the blood flow at the carotid artery and its bifurcation using mice models. 
We used 6 different models where high RDW was induced through different conditions. We 
triggered inflammation-dependent anisocytosis in mice through injection of CT 26 colon 
tumor cells that resulted in high RDW within 2 weeks. The second group of mice received 
erythropoietin intravenously for 4 subsequent days. The third group of mice were subjected 
to a low iron diet for 4 weeks and had 0.6 mL of blood drawn once a week, for a period of 3 
weeks. This triggered anaemia and induced inflammation-independent anisocytosis. The 
other experimental groups comprised of the transgenic mice commercially acquired from 
Jackson laboratory that exhibited abnormalities related to red blood cell production and 
RDW. Finally, the control mice constituted healthy, untreated animals.  
The data was acquired using a Varian 9.4T MRI scanner with a 30cm bore. We used digital 
image processing techniques to isolate blood flow information by applying an integral 
analysis on time varying flow field. Our results showed that the healthy mice have a higher 
volumetric blood flow rate in the external arteries compared to transgenic, tumorous, 
anaemic, and EPO- treated mice. The flow field of healthy mice was parabolic in shape, 
indicating that turbulence is likely of secondary importance and the shape of the flow field 
in the external arteries for EPO treated mice was found to vary the least over the cardiac 
cycle(s), indicating a change in blood rheology. This could largely be because of blood cell 
concentration, shape and distribution close to the artery wall and far away[347]. Due to the 
complex nature of blood and the diversity in the cases considered in our study, it was difficult 
to pinpoint factors governing variations in the flow profiles. Hence, the shape of the blood 
flow profile was discussed in terms of two common profiles seen in fluid mechanics: 
parabolic, and plug flow (i.e. pluggish in shape).  This is attributed to turbulent flow, that is 
pluggish in shape. The control cases are less pluggish in shape than the anaemic, EPO, 
transgenic, and tumorous mice models, indicating that turbulence due to fluctuations is of 
secondary importance. 
The role of hemodynamic forces was first proposed with observations of initial atherosclerotic 
lesions typically at arterial bends and branches with a disrupted flow. This flow pattern included 
recirculation eddies and change in direction with respect to space (reattachment and flow 
separation) and time (reciprocating flow).[39-42] Recent research also shows that this kind of 
flow and the associated reciprocating and low shear stress bring about a constant activation of 
several atherogenic genes in ECs. Through our studies, we found that changes in morphology 
of red blood cells is related to the size and shape of the cells. These are direct factors that change 
blood flow and the mode of interactions of cellular components of blood with the vascular wall. 
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We also observed that a high RDW is a predictive factor for interaction between cellular 
components of blood and the vascular wall. These interactions can lead to increased 
inflammation in the vessels and initiation of thrombosis.  
Study 3: 
Cytomegalovirus (CMV) is a virus that remains latent in the body after a primary infection. 
Studies have shown its potential involvement in several types of cancer. CMV is belongs to 
the family Herpesviridae and the subclass Betaherpesviridae. Emerging evidence indicate 
that CMV, which is not considered as an oncogenic virus, is highly present in several types 
of cancer.  For instance, over 90% of glioblastoma, neuroblastoma, medullblastoma, colon, 
breast and prostate cancers are positive for CMV proteins and nucleic acids. The viral 
proteins are also detected in lymph node and brain metastases of colon and breast cancer 
patients. However, it is rarely found in healthy tissue surrounding the primary tumor[348, 
349]. Although HCMV is found in lymph node and distant metastases, the potential virus 
related 
mechanisms of metastasis promotion are not understood. [221, 222] Through this study, we 
investigated the role of murine CMV (MCMV) on the progression of colon cancer using a 
combination of in vivo and in vitroapproaches.  In vitro, we verified that MCMV could infect 
CT26 murine colon cancer cells and that the cells express immediate early (IE) proteins. We 
found that the percentage of cells expressing IE increased in a dose dependent manner with 
increasing MOI’s. 12 – 20 % of the cells expressed IE proteins at 3 days’ post infection, as 
determined by immunoflorescence staining and flow cytometry, respectively. The IE proteins 
are regulatory proteins that are expressed at a very early stage in the virus cycle. They regulate 
the expression of other viral and cellular genes and are important in mediating tumor 
transformation. For instance, studies show that IE1induces high telomerase activity by 
interacting with SP1 binding sites in the hTERT promoter, a key step in tumor 
transformation.[350] The IE 72 gene also promotes proliferation of dormant cells by 
alleviating the repression of transcription factor p 107 which in turn activates E2F promoters. 
IE2-86 can also drive cells into S phase and prevent cellular DNA synthesis. This can 
possibly occur through interaction with minichromosome maintenance 3 (MCM3)-
associated protein (MCM3AP).[351] 
We next assessed the effect of MCMV infection on cell proliferation. Cells were infected 
with MCMV at M.O. I`s 0.5, 1 and 5, and were assessed for cell proliferation on days 1 3 and 
6-post infection. We observed that MCMV infected cells proliferated at a lower rate 
compared to the uninfected cells. HCMV is known to arrest the cell cycle and block DNA 
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replication. Studies have shown that HCMV halts the cell cycle in G1 phase followed by a 
block in replication of cellular and viral DNA. IE72 blocks the cell cycle in G2/M phase 
while IE86 can block the cell cycle at the G/S boundary.[352, 353] Hence the decrease in 
cellular proliferation in vitrois consistent with the effects the virus has on the host cell. We 
then assessed the effect of MCMV infection on invasion and observed that the percentage of 
infected cells that invaded and migrated through a porous membrane was significantly higher 
compared to the non-infected cells. These results indicated a possible enhanced invasive 
capacity of CT 26 tumor cells. 
Next, we used an animal model of colon cancer and examined the effect of MCMV infection 
on tumor growth, metastatic potential and tumor characteristics. Three groups were assessed 
the first group (MCMV infected mice) were injected with 200 µl of MCMV intraperitoneally. 
Three days later CT26 colon cancer cells (3 x 10^6 / mouse) were subcutaneously implanted 
on the flank of balb/c mice. In the second group (MCMV infected cells), we infected CT26 
cancer cells (3 x 10^6) with an MOI of 0.5 (virus titer1.8x 10^6) three days prior to 
implantation in mice. The cells contained a mixture of uninfected and infected cells as (ratio 
0.25:0.75- Infected – Uninfected). The third group served as the control group; mice were 
injected with the same number of uninfected CT26 cells into the mice as both the other 
groups. We assessed tumor growth over a period of two weeks (measured on alternate days 
starting on day 5) in all the animals. We found that the control group and the group infected 
with MCMV had similar tumor growth rates, while the MCMV infected cells group had no 
visible tumors after 15 days. Thus, MCMV did not enhance tumor growth at the injection site  
We then quantified the number of circulating tumor cells (CTCs) in the bone marrow and 
found that this number was significantly lower in the infected groups (MCMV infected mice 
and MCMV infected cells) compared to the control group. However, when we quantified the 
number of metastatic loci in the lungs, we found a significant increase of micro metastasis in 
the infected groups compared to control mice. In agreement with this observation, in 
vitroinfection demonstrated increased ability of infected cells to invade and migrate. A 
probable explanation is that the migratory cells from infected mice are capable of rapidly 
colonizing metastatic niches and spend little time in the circulation.  This could be due to 
CMV affecting the cadherin function, which in vivo may lead to induction of trans-
endothelial migration, and possibly to metastasis. Also, CMV infection leads to enhanced 
invasiveness of the infected cells, for instance, CMV infected neuroblastoma cells exhibit 
increased invasive capacity mediated via VLA-5 α1β 5 integrin along with neural adhesion 
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cell molecule (CD56). [349]The viral receptor M33, the murine counterpart of the HCMV 
US28 receptor stimulates cell migration through a ligand independent process. [252]  
From our animal models, we observed that while the infected cells did not give rise to tumors, 
the uninfected and systemically infected mice grew tumors at similar rates. We could not detect 
viral particles in tumors using quantitative PCR, IHC on tumor tissues. However, they formed 
significantly increased number of micro metastases in the lung. It is possible that the expression 
levels were much lower than the sensitivity of the methods used. Another possible explanation 
is that CMV modulated cancer through a hit and run mechanism, as has been described by other 
investigators.  
We characterized the tumor vasculature to assess differences in tumors from infected and 
uninfected models by immunohistochemical staining for smooth muscle alpha (SMA) and 
lectin. We found a significant increase in the expression of the SMA protein in the infected 
group compared to the uninfected group of mice whereas expression of lectin was not 
significantly different. We also assessed the presence of CD45+ leukocytes and CD68+ 
macrophages and found a significant increase in the presence of both these cell types in the 
infected group compared to the control which indicate an enhance immune response to the 
virus. 
We further conducted an RNA array analysis on 5 samples from each group collected post 
the metastatic study. The micro-array data highlighted changes in expression of angiogenic 
and inflammatory cytokines along with several chemokines and apoptotic factors which were 
upregulated in the infected groups compared with the controls. Surprisingly, the family of 
proteins that was mostly upregulated in tumors from infected mice were cytokeratins. By 
immunostaining, we verified that cytokeratin expression was upregulated also at protein level 
in the tumors. Hence, we hypothesized that MCMV infection leads to upregulation of 
cytokeratins (CK) and results in metastasis.  
To evaluate this, further we conducted an RNA array analysis on CT26 cells that were 
infected in vitro. While we found an upregulation of several angiogenic factors and 
inflammatory cytokines in the MCMV infected CT26 cells in vitro, we did not observe a direct 
upregulation of any of the cytokeratins that were observed to be affected in the MCMV infected 
mice. Instead, the virus appears to induce high cytokeratin expression by indirect effects. To 
assess the association of CMV related induced CK expression in tumor samples from patients, 
we studied tissue micro array (TMAs) tumor samples from colon cancer patients. Tissue 
sample sections were stained for HCMV IEA, pp65 and LA proteins and CK 1, 2 and 14. 
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   All the samples were graded as negative, low and high expression. We found a strong 
association between the level of expression of CKs and CMV proteins. These observations 
indicate that the virus induces cytokeratin expression via indirect mechanisms that may 
involve the immune response against the virus in vivo. We found no direct evidence of virus 
induced expression of these in vitroCytokeratins have been utilized as tumor markers for 
many decades.[354] Recent studies have shed light into their role during progression to 
metastasis. For example, Keratin 14 as a key regulator of metastasis; polyclonal breast cancer 
metastasis arises from collective dissemination of these K-14+ tumor clusters. The study 
revealed systematic changes in the relative proportions of K14+ and K14− cells from 
micrometastatic to macrometastatic stages.  Keratin was also shown to be involved in salivary 
adenoid cystic carcinoma, where elevated levels of keratin expression were associated with 
bad prognosis. The study suggested that K14 expression enabled collective cancer cell 
invasion. Another study reported the involvement of keratin in metastasis of lung carcinoma. 
The study showed that in lung squamous cell carcinoma(LSCC), CK 14 was expressed in the 
tumor cell nests showing stromal invasion with fibrosis and lymph node metastases. This 
indicated its involvement in proliferation and metastasis of LSCC[355] 
In agreement with this observation, we also propose the involvement of cytokeratins in cancer 
metastasis. The metastases of infected animals (brain and lungs, data now shown) had highly 
enhanced expression levels of cytokeratins.  
In conclusion, our data suggests that in vitroCMV promotes invasion and migration of CT 
26 murine colon cancer cells, while CMV does not affect tumor growth but increases 
incidence of metastasis in the lungs. We also found through RNA array analysis that 
cytokeratins 1, 2 and 14 are upregulated between sixty to hundred times in the infected 
models compared to the uninfected.  Collectively, through our study we suggest that CMV 
may promote colon cancer metastasis through a cytokeratin mediated pathway.  
Study 4: 
The CCAAT-enhancer binding protein β (C/EBPβ) is a transcription factor that plays a key 
role in the development of the mammary gland and it is also involved in breast cancer 
progression. In vitroand in vivo studies have showed a potential substantial role of C/EBPβ 
isoforms in mammary gland development and breast cancer.[305-307]  Studies, using C/EBPβ-
/- mice, revealed that C/EBPβ is vital for ductal morphogenesis, functional differentiation in the 
murine mammary gland and epithelial cell proliferation.[308-310] 
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 A previous study by our group showed that loss of C/EBPβ enhances the metastatic spread of 
mouse mammary tumor cells but did not elucidate the mechanism behind this observation. 
Therefore, through this study, we intended to further explain link between C/EBPβ and 
metastasis formation along with defining the relationship between C/EBPβ and survival of 
breast cancer patients.  
To test the hypothesis that C/EBPβ is involved in breast cancer progression, we first analysed 
a tissue microarray containing 137 breast cancer patient samples that were 
immunohistochemically stained for C/EBPβ. This was followed by a qualitative scoring of 
C/EBPβ staining in relationship to breast cancer progression. All samples were graded on 0-2 
based on expression and analysed by a pathologist. We observed the presence of a strong 
nuclear positive staining in the normal breast tissue and in some ductal cancer in situ (DCIS) 
cases. However, the expression of C/EBPβ was lower in DCIS compared to the expression in 
normal breast tissue. In many nodules, the expression was typically present in the basal layer 
surrounded by desmoplastic (growth of connective / fibrous tissue) stroma with lymphocyte 
infiltration. Thus, the intensity of C/EBPβ staining was reduced in case of inflammation 
combined with desmoplastic reaction. Reduced C/EBPβ staining was strongly evident mainly 
in areas of micro invasive cancer. Thus, our results indicate that C/EBPβ may play a role in 
breast cancer progression and its association to inflammation.  
We next assessed the relation of C/EBPβ expression to overall survival of patients using Cox 
proportional hazards and Kaplan-Meier analysis in univariate and multivariate analysis. The 
samples were adjusted for established prognostic factors. Two factors, tumor size and C/EBPβ 
expression were independent predictors of overall survival (OS). Lack of C/EBPβ expression 
was associated with shorter OS of breast cancer patients compared to higher C/EBPβ 
expression. These results show that C/EBPβ expression is associated significantly with OS, 
and relapse-free survival (RFS).  
We used a 4T1 mouse model to study the effect of C/EBPβ on breast cancer. We implanted 
two groups of 4T1 cells– one referred to as sh Control that expressed wild type C/EBPβ and 
the second one -sh C/EBPβ, with silenced expression of C/EBPβ. These cell lines were 
implanted into two groups of isogenic BALB/c mice. We measured, tumor growth, CTC 
dissemination and metastasis formation between the groups. We found that loss of C/EBPβ 
expression influenced tumor growth and morphology. C/EBPβ-silenced tumors were smaller 
compared to the non-silenced tumors, despite no difference in proliferation rate assessed by 
the in vitroassay. These results indicate that C/EBPβ does not directly control tumor growth, 
but is rather affected by other in vivo factors. Furthermore, we observed a striking 
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morphological difference between the tumors. The group with the wildtype C/EBPβ grew 
tumors that were characterized by a large central necrosis, whereas the C/EBPβ-silenced group 
grew solid tumors with an expansive growth pattern and inflammation surrounding them. This 
observation can be explained by the former study where we showed the involvement of the 
C/EBP family in vessel formation, here C/EBPδ was shown to regulate VEGEF C autocrine 
signaling in lymphangiogenesis in lung cancer.[357]  
To further characterize the effect of C/EBPβ on the tumor, tumor vasculature was primarily 
analyzed by immunohistochemical staining for endothelial cell marker CD31. We observed an 
increase in the number of vessels in C/EBPβ-silenced tumors compared to the wildtype. We 
next stained for both CD31 and a pericyte marker NG2. The results were analysed using 
Visiopharm software. Upon evaluating features such as vessel length, area, number of 
branchpoints, pericyte coverage of the vessels no significant difference was found between the 
two groups.  
To further study the effect of C/EBPβ on metastasis formation, we focused on the presence of 
CTCs in the bone marrow and the blood along with the metastatic nodules in distant organs. 
We labelled cells with GFP for this purpose. No significant differences were observed in terms 
of CTCs in the blood and bone marrow between the groups. We next evaluated if C/EBPβ 
knockdown affected metastatic spread by analysing the lungs of tumor-bearing mice Our 
results indicated that the ratio of mice with lung metastasis/without metastasis was 
significantly higher in the sh C/EBPβ group than the controls. This indicated that loss of 
C/EBPβ promotes metastatic spread of mammary 4T1 tumors. Furthermore, morphological 
analysis through H & E staining indicated evident chronic inflammation in lungs of mice with 
C/EBPβ knockdown tumors compared to lungs of C/EBPβ expressing mice. This observation 
agrees with the fact that C/EBPβ affects development of an inflammatory process. This was 
also confirmed in the TMA analysis, where inflammation was more prominent in tumors with 
lower C/EBP  expression  
To further study the mechanism of how C/EBP affects formation of metastasis, we conducted 
a microarray analysis using RNA extracts from 4T1 cells expressing C/EBP shRNA and control 
shRNA. The analysis divulged 559 statistically different sets of genes between sh control and sh 
C/EBP cells. Analysis done using Panther database service showed that the group of genes 
most significantly changed amongst them were genes related to inflammation. Representative 
genes included MHCIIα, MHCIIβ and HLACIIγ. Chemokines such as CCL5, CCL7 and CCL8 
were also among the highly-affected genes. 
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To see if a similar pattern is observed in the tumor, we also performed a microarray analysis on 
the tumors dissected from mice, using RNA extracts from 4T1 tumors expressing C/EBP 
shRNA and control shRNA. In this setup, 135 genes were upregulated by more than 1.3-fold. 
Upon analyzing the results further, we observed that inflammation group of genes were the most 
representative affected. Most of the genes are yet to be characterized and CD3+ lymphocytes 
were first on the list with difference equal 5 times fold. These results clearly demonstrate that 
C/EBPβ is involved in alteration of an immunological response in the tumor by directly 
regulating MHCII expression and indirectly amassing CD3+ lymphocytes in the tumor.  
To confirm this observation, we stained sh C/EBPβ tumors and sh control tumors were stained 
for CD3, CD45, CD4 and MHCII. The results indicated that C/EBPβ inhibition led to an 
increased expression of MHCII followed by an accumulation of CD45, CD3 and CD4-positive 
lymphocytes in the tumors. This was by far, the most significant difference observed between 
the tumors from morphological, microarray data and immunohistochemical analysis. 
Inflammation is known to play an important role in cancer progression. Tumors can induce T-
cell tolerance against tumor antigens, resulting in an immunosuppressive environment that is 
highly advantageous for the tumor development. For instance, extreme changes in 
myelopoiesis brought about by tumor growth resulted in recruitment of myeloid-derived 
suppressor cells. The immunoregulatory activity of these cells depend on C/EBPβ.[358] 
A probable connection between C/EBPβ, inflammation and metastasis can be provided through 
chemokines. Numerous studies demonstrated that tumor-associated chemokines and their 
receptors have an important role in shaping the metastatic process of cancer cells. Also, 
chemokines are involved in inflammation regulation within tumors and stop the host’s immune 
system from rejecting cancer. In this study, interstingly, both chemokines such as CCL2 (MCP-
1) or CCL5 have already been linked to breast cancer metastasis. CCL2, produced by stromal 
tumor cells, is involved in promotion of lung metastasis of 4T1 cells.[359]Alternatively, 
CCL5/CCR5 promotes invasion and metastasis in the aggressive, basal subtype of breast 
cancer.[360] 
In summary, we found that C/EBPβ is a predictor for overall survival in breast cancer patients, 
and that lower C/EBPβ expression affects tumor growth, morphology and lung metastasis 
formation in murine 4T1 breast cancer model.
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4 CONCLUSIONS  
In this thesis, we have focused on understanding factors contributing towards intimal formation 
post vascular injury, anisocytosis as a factor affecting blood flow in the vascular endothelium 
and factors contributing towards cancer metastasis.  
- Through study 1, we suggest that bone marrow derived cells provide reparative function in 
the initial stages of arterial injury and were subsequently eliminated probably through apoptosis 
or had a low survival rate in the endothelium. The BM derived cells localized in the intima and 
most of them expressed endothelial cell markers indicating their endothelial phenotype 
although their distribution was unequal. In the areas were the intima was thicker the cells 
expressed smooth muscle cell actin and myosin. Moreover, the bone marrow derived cells did 
not fuse with the intima. We observed that the local delivery of BM- derived endothelial cells 
to the sites of arterial injury resulted in a 1.4-fold reduction in the intimal lesions area. These 
results show that these cells are a key factor in the inhibition of intimal formation and likely 
play role in healing. The results also suggest that the BM derived ECs are of high importance 
in the initial stages of intimal formation and put forth the idea that other sources of vascular 
progenitor cells apart from bone marrow are likely the major composition of the developed 
intimal lesions. These results define the role of these cells in the development of intimal lesions 
post vascular injury and this information contributes to the existing understanding of the 
pathogenesis of intimal hyperplasia. Nonetheless, additional studies are needed in both cell 
culture systems and translational animal models to better define the phenotype of BM-derived 
endothelial cells and their progenitor cells, and characterize the specific function of these 
cells in the injured vasculature. 
- Recent research show that disturbed blood flow and the associated reciprocating and low 
shear stress bring about a constant activation of several atherogenic genes in ECs and contribute 
towards development of atherosclerotic lesions. RDW might be another factor that contributes 
to disturbed blood flow and is considered a risk factor for death in patients with cancer and 
CVD.  Through our study, by using blood flow in micro -channels and analysis with optical 
coherence tomography, we have, for the first time, shown that changes in morphology of red 
blood cells is related to the size and shape of the cells and that these are direct factors that 
change blood flow and the mode of interactions of cellular components of blood with the 
vascular wall. We also observed that RDW is a predictive factor for interaction between cellular 
components of blood and vascular wall. These interactions can lead to increased inflammation 
in the vessels and thrombosis initiation.  
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Therefore, anisocytosis measured by RDW may be a useful predictive factor for patients with 
vascular diseases.  
-Cancer metastasis is a leading cause of death worldwide despite improvements in diagnosis, 
adjuvant therapies and surgical techniques. An aberrant vasculature (tumor vasculature) leads 
to metastasis. Through study 3 and 4 we investigated factors contributing towards metastasis.  
Through study 3 we investigated the role of murine CMV in colon cancer metastasis. We 
found that in vitro, MCMV promoted the migration and invasive ability of CT26 colon cancer 
cells. In vivo, MCMV increased the expression smooth muscle alpha actin and lectin and 
significantly increased the metastatic potential of CT26 cells. RNA array analysis indicated 
that MCMV infection increased the expression of high molecular weight cytokeratin in 
tumors along with various chemokines and angiogenic factors. Analysis of human colon 
cancer specimens confirmed a significant association between CMV protein expression and 
cytokeratin 1, 2 and 14 expressions. Collectively our data suggest that CMV may promote 
colon cancer metastasis through a cytokeratin mediated pathway. The mechanism warrants 
further investigation. Understanding this mechanism could provide new therapeutic advances 
for colon cancer patients.  
-Finally, through study 4, our data suggests that C/EBPβ is a predictor for overall survival in 
breast cancer patients, and that lower C/EBPβ expression affects tumor growth, morphology 
and lung metastasis formation in murine 4T1 breast cancer model. The mechanism is related 
to immunological response, and occurs through activation of MHCII and recruitment of CD4+ 
lymphocytes mediated by C/EBPβ. Our results suggest that C/EBPβ may be a new predictive 
factor for OS of breast cancer patients and provides new insights on C/EBPβ’s role in breast 
cancer progression. 
In summary, this work contributes to broadening the knowledge related to implications of a 
damaged vasculature in different pathologies in vascular disease and cancer and could provide 
new breakthroughs in therapies for patients. 
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